In the Literature

Hematologic Malignancies
Leukemia

Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia

Matthew Stenger  / December 10, 2017

An observational study reported in The Lancet Oncology by -Wolthers et al in the Ponte di Legno Toxicity Working Group identified characteristics and the course of asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. Kjeld Schmiegelow, MD, of The University Hospital R...

Solid Tumors
Head and Neck Cancer

Radiotherapy Fractionation for Head and Neck Cancers

Matthew Stenger  / December 10, 2017

An update of the Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck (MARCH) showed that hyperfractionated radiotherapy maintained a survival advantage over conventional radiotherapy in head and neck cancers. The findings were reported in The Lancet Oncology by Lacas et a...

Solid Tumors
Breast Cancer

Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer

Matthw Stenger  / December 10, 2017

In a study reported in JAMA Oncology, Thomas Karn, PhD, of Goethe-University Frankfurt, and colleagues found that triple-negative breast cancers with high immune gene expression levels were characterized by lower clonal heterogeneity, reduced copy number alterations, and lower somatic mutation,...

Solid Tumors
Breast Cancer

Partial-Breast and Reduced-Dose Radiotherapy After Breast-Conserving Surgery

Matthew Stenger  / December 10, 2017

The UK IMPORT LOW phase III trial has shown noninferiority in local relapse for partial-breast and reduced-dose vs standard whole-breast radiotherapy after breast-conserving surgery in early breast cancer. These study results were reported by Charlotte E. Coles, PhD, of the University of Cambri...

Solid Tumors
Breast Cancer

AKT Inhibitor Ipatasertib in Metastatic Triple-Negative Breast Cancer

Matthew Stenger  / December 10, 2017

The randomized phase II LOTUS trial has shown improved progression-free survival with the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer. These results were reported by Sung-Bae Kim, MD, of the University of Ulsan ...

Prostate Cancer

Comparison of Circulating Tumor DNA and Metastatic Tissue Biopsy in Identifying Mutations in Prostate Cancer

Matthew Stenger  / November 25, 2017

In a study reported in the Journal of the National Cancer Institute, Wyatt et al found high agreement between driver mutations in plasma circulating tumor DNA (ctDNA) and metastatic tissue biopsy in castration-resistant prostate cancer. Martin Gleave, MD, and Alexander Wyatt, DPhil, of Van...

Prostate Cancer

Adverse Pathologic Findings in Low-Volume Intermediate-Risk Prostate Cancer

Matthew Stenger  / November 25, 2017

In a single-center analysis reported in JAMA Oncology, Hiten D. Patel, MD, MPH, of The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, and colleagues found that among men undergoing elective radical prostatectomy, those with low-volume intermediate-risk d...

Prostate Cancer

Bone-Targeted Therapies for Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

Matthew Stenger  / November 25, 2017

Among men diagnosed with prostate cancer, about one in two will receive androgen-deprivation therapy, which is associated with many potential adverse side effects, including significant bone loss and increased risk for low trauma or fragility fractures similar to those found in people with prim...

Prostate Cancer

Health-Related Quality of Life With Immediate vs Delayed ADT in Prostate Cancer

Matthew Stenger  / November 25, 2017

In a health-related quality-of-life study among patients in the phase III TOAD trial, immediate vs delayed androgen-deprivation therapy (ADT) was associated with early worsening of androgen-deprivation therapy–related symptoms but few other comparative adverse effects on functioning or quality ...

Gynecologic Cancers

Olaparib Tablets as Maintenance in BRCA1/2-Mutant Relapsed Ovarian Cancer

Matthew Stenger  / November 25, 2017

A phase III trial (SOLO2/ENGOT-Ov21) has shown improved progression-free survival with an olaparib tablet formulation vs placebo as maintenance therapy in patients with BRCA1/2-mutant platinum-sensitive relapsed ovarian cancer. These study results were reported by Eric Pujade-Lauraine, MD, of t...

Breast Cancer

BRCA1/2 Status in Response to Therapy in Triple-Negative Breast Cancer

Matthew Stenger  / November 10, 2017

An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effect...

Breast Cancer

10-Year Follow-up on Adjuvant Therapy in Postmenopausal Early Breast Cancer

Matthew Stenger  / November 10, 2017

The 10-year follow-up of the phase III TEAM trial has shown that exemestane alone and sequential tamoxifen/exemestane provide similar outcomes as adjuvant endocrine therapy in postmenopausal women with hormone receptor–positive early breast cancer. The findings were reported in The Lancet Oncol...

Breast Cancer

Ovarian Function Recovery During Anastrozole Therapy in Postmenopausal Patients With Breast Cancer

Matthew Stenger  / November 10, 2017

In the phase III DATA trial reported in the Journal of the National Cancer Institute by Vivianne C.G. Tjan-Heijnen, MD, PhD, of the Maastricht University Medical Centre, the Netherlands, and colleagues, 12% of women with breast cancer who had chemotherapy-induced ovarian function failure experi...

Breast Cancer

Predisposition to Breast Cancer due to Mutations Other Than BRCA1/BRCA2 in Ashkenazi Jewish Women

Matthew Stenger  / November 10, 2017

A cohort study in Ashkenazi Jewish women with breast cancer identified mutations other than BRCA1 and BRCA2 founder alleles that were associated with cancer risk. These results were reported by Walsh et al in JAMA Oncology. Among Ashkenazi Jewish women, three mutations in BRCA1 and BRCA2 dramat...

Skin Cancer

Nivolumab Treatment Beyond Disease Progression in Advanced Melanoma

Matthew Stenger  / October 25, 2017

In a retrospective analysis reported in JAMA Oncology, Georgina V. Long, MBBS, PhD, of the Melanoma Institute Australia, North Sydney, and colleagues found that a substantial proportion of patients with advanced melanoma derived benefit from continued nivolumab (Opdivo) treatment after Response...

Solid Tumors
Lung Cancer

Tremelimumab in Previously Treated Advanced Malignant Mesothelioma

Matthew Stenger  / October 25, 2017

In the randomized phase IIB DETERMINE trial, the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor tremelimumab did not improve overall survival vs placebo as second- or third-line treatment of relapsed malignant mesothelioma. These findings were reported in The Lancet Oncology by ...

Solid Tumors
Hepatobiliary Cancer

Adding Sorafenib to Transarterial Chemoembolization in Hepatocellular Carcinoma

Matthew Stenger  / October 10, 2017

As reported in The Lancet Gastroenterology & Hepatology by Tim Meyer, MBBS, of the University College London, and colleagues, the UK phase III TACE 2 trial has shown no progression-free survival benefit with the addition of sorafenib (Nexavar) to transarterial chemoembolization in patients ...

Solid Tumors
Gynecologic Cancers

Performance Measures for Cervical Cancer Screening

Matthew Stenger  / October 10, 2017

Health-care systems use performance measures for cervical cancer screening based on guidelines from such organizations as the American College of Obstetricians and Gynecologists to monitor the appropriateness of cervical cancer screening. According to the performance measure in the Healthcare E...

Solid Tumors
Skin Cancer

Adjuvant Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma

Matthew Stenger  / October 10, 2017

The phase III Checkmate 238 trial has shown improved recurrence-free survival with adjuvant nivolumab (Opdivo) vs ipilimumab (Yervoy) in patients with resected advanced melanoma. The findings were reported by Jeffrey Weber and colleagues in The New England Journal of Medicine. Study Details I...

Solid Tumors
Prostate Cancer

Association Between Vasectomy and Prostate Cancer

Matthew Stenger  / October 10, 2017

A systematic review and meta-analysis has found no association between vasectomy and high-grade, advanced, or fatal prostate cancer but a weak association with any prostate cancer. These findings were reported in JAMA Oncology by Bimal Bhindi et al. R. Jeffrey Karnes, MD, of the Mayo Clini...

Solid Tumors
Head and Neck Cancer
Gastroesophageal Cancer

Addition of Cetuximab to Concurrent Chemoradiation in Esophageal Cancer

Matthew Stenger  / October 10, 2017

The phase III NRG Oncology RTOG 0436 trial has shown no survival benefit of adding cetuximab (Erbitux) to paclitaxel/cisplatin and radiation therapy in patients with esophageal cancer treated without surgery. These results were reported by Mohan Suntharalingam, MD, MBA, of the Marlene and Stewa...

Breast Cancer

Trastuzumab-Based Regimens in Older Women With Early Breast Cancer

Matthew Stenger  / September 25, 2017

A comparative analysis of outcomes with two different trastuzumab (Herceptin)-based adjuvant regimens in older women with early HER2-positive breast cancer found little difference in safety and efficacy between treatments. The study was reported by Katherine E. Reeder-Hayes, MD, MBA, of the Uni...

Adding Midostaurin to Chemotherapy in AML With FLT3 Mutation

Matthew Stenger  / September 25, 2017

In a phase III trial (Cancer and Leukemia Group B 10603 [RATIFY]/Alliance) reported in The New England Journal of Medicine, Stone et al found that the addition of midostaurin (Rydapt) to standard chemotherapy improved overall survival in patients with newly diagnosed acute myeloid leukemia (AML) wit...

Neurocognitive Function in Patients Treated for B-Lineage ALL

Matthew Stenger  / September 25, 2017

In a Children’s Oncology Group (COG) study (AALL06N1) reported in the Journal of Clinical Oncology, Hardy et al found that age < 10 years at diagnosis was associated with poorer neurocognitive function in patients with high-risk B-lineage acute lymphoblastic leukemia (ALL) regardless of meth...

Breast Cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Breast Cancer

Matthew Stenger  / September 10, 2017

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology...

CNS Cancers

Dinutuximab vs Temsirolimus in Combination Therapy for Children With Resistant Neuroblastoma

Matthew Stenger  / September 10, 2017

A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab (Unituxin) plus irinotecan/temozolomide as a regimen to be further evaluated in the treatment of pediatric patients with refractory or relapsed neuroblastoma. Study results were r...

Colorectal Cancer

First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Colorectal Cancer

Matthew Stenger  / September 10, 2017

A phase III trial has shown no significant difference in overall survival with first-line cetuximab (Erbitux) vs bevacizumab (Avastin) plus chemotherapy in patients with advanced or metastatic KRAS wild-type colorectal cancer. These study findings were reported by Alan Venook, MD, of University...

Gastrointestinal Cancer

Relationship Between Molecular Subtypes of Gastric Cancer and Prognosis

Matthew Stenger  / September 10, 2017

In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability, genomically stable, and chromosomal instability. However, their clinical significance is unknown.  Now, a study by Bo Hwa Sohn, PhD, ...

Head and Neck Cancer
Solid Tumors

PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma

Matthew Stenger  / August 25, 2017

According to a study by Heath D. Skinner, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squam...

Solid Tumors
Skin Cancer

Dabrafenib Plus Trametinib in BRAF V600–Mutant Melanoma Brain Metastases

Matthew Stenger  / August 25, 2017

A phase II trial has shown that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinst) produces responses in brain metastases in patients with BRAF V600–mutant melanoma. These findings were reported by Michael A. Davies, MD, of The University of T...

CNS Cancers

Vaccine-Chemotherapy Combination in Glioblastoma

Matthew Stenger  / August 10, 2017

Despite highly aggressive therapy that includes maximal tumor resection, high-dose radiation, and temozolomide chemotherapy, the prognosis for patients with newly diagnosed glioblastoma is dismal, with a median survival of less than 15 months, prompting researchers to study novel approache...

Lung Cancer

Sacituzumab Govitecan in Metastatic NSCLC

Matthew Stenger  / August 10, 2017

As reported by Rebecca Suk Heist, MD, MPH, of Massachusetts General Hospital, and colleagues in the Journal of Clinical Oncology, the antibody-drug conjugate sacituzumab govitecan showed activity in patients with previously treated metastatic non–small cell lung cancer (NSCLC). Sacituzumab targ...

Cost of Care

Cost of Hospitalization for Cancer-Related Neutropenia or Fever

Matthew Stenger  / August 10, 2017

In a study of 2012 data, Eric Tai, MD, of the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, and colleagues estimated that average costs per hospital stay for cancer-related neutropenia or fever were approximately $25,000, with a total cost of more than $...

Solid Tumors

First-in-Class T-Cell Stimulator Varlilumab in Advanced Tumors

Matthew Stenger  / August 10, 2017

A phase I study reported by Howard A. Burris, MD, of Sarah Cannon Research Institute, Tennessee Oncology, and colleagues in the Journal of Clinical Oncology has shown that the first-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumor...

Bladder Cancer

Avelumab in Refractory Metastatic Urothelial Carcinoma

Matthew Stenger  / July 25, 2017

The programmed cell death ligand 1 (PD-L1)–inhibitor avelumab (Bavencio) has shown activity in patients with refractory metastatic urothelial cancer, according to findings in a phase Ib study reported by Andrea B. Apolo, MD, of the Genitourinary Malignancies Branch, Center for Cancer Research, Natio...

Lung Cancer

Prophylactic Cranial Irradiation vs Observation in Extensive-Disease Small Cell Lung Cancer

Matthew Stenger  / July 25, 2017

A Japanese phase III trial has shown no survival benefit of prophylactic cranial irradiation vs observation in patients with extensive-disease small cell lung cancer who had any response to platinum-based doublet chemotherapy and no brain metastases at baseline. These findings were reported in The L...

Lymphoma

Final Results of European Trial in Mucosa-Associated Lymphoid Tissue Lymphoma

Matthew Stenger  / July 10, 2017

The final results of the European phase III International Extranodal Lymphoma Study Group (IELSG)-19 trial, reported in the Journal of Clinical Oncology by Emanuele Zucca, MD, of the IELSG Operation Office, Oncology Institute of Southern Switzerland, and colleagues showed that event-free and pr...

Leukemia

Blinatumomab in B-Precursor Acute Lymphoblastic Leukemia

Matthew Stenger  / July 10, 2017

In a phase II trial reported in the Journal of Clinical Oncology, Giovanni Martinelli, MD, of S. Orsola University Hospital, Bologna, and colleagues found that blinatumomab (Blincyto) produced complete responses in patients with relapsed/refractory Philadelphia chromosome–positive B-precursor a...

Prostate Cancer

Testosterone Replacement Therapy and the Risk of Prostate Cancer

Matthew Stenger  / June 25, 2017

In a Swedish study reported in the Journal of Clinical Oncology, Stacy Loeb, MD, of New York University, and colleagues found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among...

Pancreatic Cancer

Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma

Matthew Stenger  / June 25, 2017

In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. John P. ...

Breast Cancer

Anthracyclines in HER2-Negative Breast Cancer

Matthew Stenger  / June 10, 2017

As reported by Joanne L. Blum, MD, PhD, of Baylor University Medical Center, Texas Oncology, and colleagues in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane ...

Leukemia

Clofarabine-Based Consolidation in Younger Patients With AML

Matthew Stenger  / June 10, 2017

In a French randomized phase II trial reported in the Journal of Clinical Oncology, Thomas et al found that clofarabine-based consolidation may provide improved relapse-free survival vs conventional high-dose cytarabine in postremission treatment in younger patients with acute myeloid leukemia (AML)...

Skin Cancer

Immunotherapy Clinical Trials in Metastatic Melanoma

Matthew Stenger  / May 25, 2017

A Danish study reported in the European Journal of Cancer by Marco Donia, MD, PhD, of the Center for Cancer Immune Therapy, Herlev Hospital, Denmark, and colleagues indicates that more than half of patients with metastatic melanoma do not satisfy requirements for enrollment in phase III trials of im...

Breast Cancer

Cholesterol-Lowering Medication Use and Breast Cancer Outcome

Matthew Stenger  / May 25, 2017

In a study reported in the Journal of Clinical Oncology, Signe Borgquist, MD, PhD, of Lund University, Sweden, and colleagues found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone receptor–positiv...

Palliative Care

Pediatric Oncology Patient and Parent Attitudes on Early Palliative Care Integration

Matthew Stenger  / May 25, 2017

Few pediatric oncology patients or their parents expressed negative attitudes toward early integration of palliative care during cancer treatment, in a study by Deena R. Levine, MD, of the Division of Quality of Life and Palliative Care, St Jude Children’s Research Hospital, and colleagues reported ...

Lung Cancer

Gefitinib or Erlotinib vs Chemotherapy in Advanced NSCLC

Matthew Stenger  / May 10, 2017

In an individual patient data meta-analysis reported in the Journal of the National Cancer Institute, Lee et al found no difference in overall survival for first-line treatment with the first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib (Iressa) or erlotini...

Lung Cancer

Never Smokers Account for Increased Proportion of NSCLC Cases

Matthew Stenger  / May 10, 2017

In a retrospective study in three U.S. institutions reported in the Journal of the National Cancer Institute, Pelosof et al found that never smokers accounted for an increasing proportion of cases of non–small cell lung cancer (NSCLC) during the period from 1990 to 2013. Joan Schiller, MD, of the In...

Gynecologic Cancers

Sentinel Lymph Node Biopsy vs Lymphadenectomy in Endometrial Cancer Staging

Matthew Stenger  / May 10, 2017

In the FIRES prospective cohort study reported in The Lancet Oncology, Emma C. Rossi, MD, of the University of North Carolina, Chapel Hill, and colleagues found that sentinel lymph node mapping was highly accurate in detecting metastases compared with complete lymphadenectomy in women with endometri...

Skin Cancer

Intermittent Vismodegib Regimens in Basal Cell Cancers

Matthew Stenger  / May 10, 2017

In a phase II trial reported in The Lancet Oncology, Brigitte Dréno, MD, of Nantes University, Nantes, France, and colleagues found that two long-term intermittent vismodegib (Erivedge) dosing regimens provided a similar reduction in the number of clinically significant basal cell carcinomas among p...

Multiple Myeloma

Link Between Obesity and Transformation of MGUS to Myeloma

The ASCO Post  / April 25, 2017

In a population-based cohort study reported in the Journal of the National Cancer Institute, Su-Hsin Chang, PhD, of the Washington University School of Medicine, and colleagues found that overweight and obesity were associated with an increased risk of transformation of monoclonal gammopathy of unde...

Lung Cancer

Adding Bevacizumab to Cisplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer

The ASCO Post  / April 25, 2017

In an Italian phase III trial reported in the Journal of Clinical Oncology, Marcello Tiseo, MD, of Azienda Ospedaliero-Universitaria, Parma, Italy, and colleagues found that adding first-line bevacizumab (Avastin) to cisplatin/etoposide did not prolong overall survival in patients with extensive-dis...

Colorectal Cancer

Reducing Debilitating Symptoms of Advanced Colorectal Cancer

The ASCO Post  / March 25, 2017

In a phase III trial reported in The Lancet Oncology, Tamas Hickish, MD, of Poole Hospital NHS Foundation Trust, Dorset, England, and colleagues found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite ...

Prostate Cancer

Potential Surrogate for All-Cause Mortality Risk in Localized Prostate Cancer

The ASCO Post  / March 25, 2017

In a study reported in JAMA Oncology, Trevor J. Royce, MD, of Harvard Radiation Oncology Program, Brigham and Women’s Hospital, and colleagues found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and androgen-...

Kidney Cancer

Intermittent Sunitinib in Metastatic Renal Cell Carcinoma

The ASCO Post  / March 25, 2017

In a phase II study reported in the Journal of Clinical Oncology, Moshe C. Ornstein, MD, of Cleveland Clinic Taussig Cancer Institute, and colleagues found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. In t...

Breast Cancer

Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy

The ASCO Post  / March 25, 2017

In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings in...

Leukemia
Cost of Care

Financial Burden of Targeted Oral Therapy for Patients With Chronic Myeloid Leukemia

The ASCO Post  / March 25, 2017

In a study reported in the Journal of Oncology Practice, Chan Shen, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the Medic...

Issues in Oncology

Potential Biomarker of Recurrent Venous Thromboembolism in Patients Receiving Anticoagulants

The ASCO Post  / March 10, 2017

In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Alok A. Khorana, MD, of the Cleveland Clinic, and colleagues found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on ...

Colorectal Cancer

Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer

The ASCO Post  / March 10, 2017

In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. Heather Hampel, MS, CGC, of The Ohio State University Comprehensive Cancer Center, is...

Colorectal Cancer

Addition of Cetuximab to Chemoradiotherapy for Anal Carcinoma

Charlotte Bath  / March 10, 2017

In a phase II trial (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group E3205) reported in the Journal of Clinical Oncology, Garg et al found that the addition of cetuximab (Erbitux) to definitive chemoradiotherapy appeared to reduce the rates of l...

Bladder Cancer

Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

The ASCO Post  / March 10, 2017

As reported by Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, Temple Health, and colleagues in The Lancet Oncology, pembrolizumab (Keytruda) has shown activity in patients in the locally advanced or metastatic urothelial carcinoma cohort included in the phase Ib KEYNOTE-012 trial. In the stu...

Breast Cancer

Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors

The ASCO Post  / February 25, 2017

In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype derive...

Gynecologic Cancers

Rucaparib in Relapsed Platinum-Sensitive High-Grade Ovarian Cancer

The ASCO Post  / February 25, 2017

In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Elizabeth M. Swisher, MD, of the University of Washington, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapse...

Gynecologic Cancers

Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer

The ASCO Post  / February 25, 2017

Kathleen N. Moore, MD, of Stephenson Cancer Center, The University of Oklahoma, and colleagues found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a pha...

Pancreatic Cancer

Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer

The ASCO Post  / February 25, 2017

Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has f...

Pancreatic Cancer

First-in-Class Rovalpituzumab Tesirine in Recurrent Small Cell Lung Cancer

The ASCO Post  / February 25, 2017

In a phase I study reported in The Lancet Oncology, Charles M. Rudin, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), produced responses in patients with recurrent...

Hepatobiliary Cancer

Effect of Sorafenib and Hepatitis Status in Advanced Hepatocellular Carcinoma

The ASCO Post  / February 25, 2017

In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C v...

Leukemia

Retinoic Acid and Arsenic Trioxide vs Retinoic Acid and Chemotherapy in APL

The ASCO Post  / February 10, 2017

As reported in the Journal of Clinical Oncology by Platzbecker et al, the final results of the Italian-German phase III APL0406 trial indicate that the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO [Trisenox]) is associated with better outcomes than standard ATRA plus chemo...

Leukemia

Postinduction MRD Predicts Outcome From Transplantation in NPM1-Mutant AML

The ASCO Post  / February 10, 2017

In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). Nicolas Bois...

Breast Cancer

Serum DNA Methylation as Predictive Marker in Metastatic Breast Cancer

The ASCO Post  / February 10, 2017

In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Kala Visvanathan, MBBS, MHS, of Johns Hopkins University, and colleagues, a cumulative methylation index was found to be predictive of progression-free surv...

Skin Cancer

Link Between Alcohol Intake and Increased Risk for Melanoma

The ASCO Post  / February 10, 2017

Although alcohol consumption is associated with increasing the risk of many cancers, including liver, pancreatic, colon, rectal, and breast, the link between alcohol and higher risk of melanoma is equivocal. Now, a large prospective study by Andrew Rivera, MD, of Harvard Medical School, Boston, and ...

Lung Cancer

Cabozantinib Alone or With Erlotinib in EGFR Wild-Type NSCLC

The ASCO Post  / January 25, 2017

Treatment with the multikinase inhibitor cabozantinib (Cabometyx) alone or with erlotinib (Tarceva) improved progression-free survival vs erlotinib alone in second- or third-line treatment of advanced nonsquamous epidermal growth factor receptor (EGFR) wild-type non–small cell lung cancer (NSCLC), a...

Hepatobiliary Cancer

Second-Line Ramucirumab in Advanced HCC

The ASCO Post  / January 25, 2017

In an exploratory analysis of the REACH trial in advanced hepatocellular carcinoma reported in JAMA Oncology, Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues found a borderline survival benefit of second-line ramucirumab (Cyramza) vs...

Sarcoma

Regorafenib in Advanced Nonadipocytic Soft-Tissue Sarcoma

The ASCO Post  / January 25, 2017

Mir et al found that regorafenib (Stivarga) was active in patients with advanced nonadipocytic soft-tissue sarcoma previously treated with an anthracycline, according to a French-Austrian phase II trial reported in The Lancet Oncology. Regorafenib, a kinase inhibitor, should be evaluated further in ...

Sarcoma

Addition of Palifosfamide to Doxorubicin in Metastatic Soft-Tissue Sarcoma

The ASCO Post  / January 25, 2017

In the phase III PICASSO III trial reported in the Journal of Clinical Oncology, Christopher W. Ryan, MD, of Oregon Health & Science University, and colleagues found that adding palifosfamide to doxorubicin did not prolong progression-free survival among patients with metastatic soft-tissue sarc...

Prostate Cancer

24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer

The ASCO Post  / January 25, 2017

In a matched retrospective analysis reported in The Lancet Oncology, Zhao et al identified and validated a 24-gene predictor of response to postoperative radiotherapy in prostate cancer. Felix Y. Feng, MD, of the University of California, San Francisco, is the corresponding author of The Lancet Onco...

Geriatric Oncology
Leukemia

Androgen Maintenance in Elderly Patients With AML

The ASCO Post  / January 25, 2017

The addition of norethandrolone as maintenance therapy improved survival in patients aged ≥ 60 years with acute myeloid leukemia (AML), according to a French phase III trial reported in the Journal of Clinical Oncology by Pigneux et al. Norbert Ifrah, MD, of CHU d’Angers, France, is the correspondi...

CNS Cancers

Weekly Vinblastine in Chemotherapy-Naive Children With Progressive Low-Grade Glioma

The ASCO Post  / December 25, 2016

In a phase II Canadian Pediatric Brain Tumor Consortium Study reported in the Journal of Clinical Oncology, Lassaletta et al found that vinblastine monotherapy was associated with response or stable disease in most children with chemotherapy-naive low-grade glioma. Vinblastine monotherapy has shown ...

Colorectal Cancer

Colonoscopy Screening in Older Adults

The ASCO Post  / December 25, 2016

A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found the...

Lung Cancer

Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC

The ASCO Post  / December 25, 2016

In a phase II trial reported in The Lancet Oncology, Glenwood Goss, MD, of The Ottawa Hospital Cancer Centre, University of Ottawa, and colleagues found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small cell...

Gynecologic Cancers

Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation

Matthew Stenger  / December 25, 2016

Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Jonathan A. Ledermann, M...

Breast Cancer
Genomics/Genetics

Use of Genetic Testing to Identify Patients With Breast Cancer at High Risk for Venous Thromboembolism

The ASCO Post  / December 25, 2016

Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...

Lung Cancer

Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer

The ASCO Post  / December 10, 2016

In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional (3D...

Head and Neck Cancer

Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck

The ASCO Post  / December 10, 2016

In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced tumor-infiltratin...

Skin Cancer

Investigational Immunotherapy for Advanced Melanoma

The ASCO Post  / December 10, 2016

The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research. IM...

Breast Cancer

Primary Care Physician Involvement in Decision-Making in Breast Cancer

The ASCO Post  / November 25, 2016

Most women with breast cancer reported high primary care physician quality, engagement, and communication, with a minority reporting high levels of primary care physician participation in treatment decisions, according to a study reported by Lauren P. Wallner, PhD, MPH, of the University of Michigan...

Breast Cancer

Genetic Markers Associated With Pathologic Complete Response Identified in HER2-Positive Breast Cancer

The ASCO Post  / November 25, 2016

In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Christos Sotiriou, MD, PhD, of Institut Jules Bord...

Prostate Cancer

Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial

The ASCO Post  / November 25, 2016

In the Prostate Cancer Prevention Trial finasteride was found to reduce the risk of low-grade prostate cancer but to have no effect on overall survival. Results of the trial, in which 18,880 men were randomized to receive finasteride or placebo for 7 years, were reported in 2003. In a recent study ...

Bladder Cancer

Nivolumab in Recurrent Advanced Urothelial Carcinoma

The ASCO Post  / November 25, 2016

In the phase I/II CheckMate 032 trial reported in The Lancet Oncology, Padmanee Sharma, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that nivolumab (Opdivo) was active in locally advanced or metastatic urothelial carcinoma progressing after platinum-based therapy. ...

Gastroesophageal Cancer

Meta-analysis Identifies New Genetic Variants for Barrett’s Esophagus and Esophageal Adenocarcinoma

The ASCO Post  / November 10, 2016

As reported in The Lancet Oncology, Puya Gharahkhani, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, and colleagues identified several new genetic risk variants for the development of Barrett’s esophagus and esophageal adenocarcinoma through a large-scale meta-analysis of ge...

Lymphoma

Higher Baseline Metabolic Tumor Volume and Poorer Outcomes in Patients With High Tumor Burden Follicular Lymphoma

The ASCO Post  / November 10, 2016

In a pooled analysis reported in the Journal of Clinical Oncology, Michel Meignan, MD, PhD, of the Université Paris-Est Créteil, and colleagues found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG P...

Lymphoma

Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients

The ASCO Post  / November 10, 2016

In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...

Skin Cancer

Study Suggests Benefit of Adjuvant Radiation Therapy but Not Chemotherapy in Some Patients With Merkel Cell Carcinoma

The ASCO Post  / November 10, 2016

In an analysis of National Cancer Data Base data reported in the Journal of the National Cancer Institute, Shailender Bhatia, MD, of the University of Washington/Fred Hutchinson Cancer Research Center, and colleagues found that adjuvant radiotherapy was associated with a survival benefit in patients...

CNS Cancers

Prevalence of Early Endocrine Disorders in Survivors of Childhood Brain Tumors

The ASCO Post  / November 10, 2016

Clement et al found that 25% of survivors of childhood brain tumors were diagnosed with endocrine disorders over 6.6 years of follow-up, based on a Dutch nationwide study reported in the Journal of Clinical Oncology. Hanneke M. van Santen, MD, PhD, of Wilhelmina Children’s Hospital, University Medic...

Pancreatic Cancer

Impact of Neoadjuvant Therapy on Survival in Resectable Pancreatic Cancer

The ASCO Post  / November 10, 2016

In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Patricio M. Polanco, MD, of the Division of Surgical On...

Lung Cancer

Enrollment Disparity in National Lung Cancer Trials

The ASCO Post  / November 10, 2016

Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...

Head and Neck Cancer

Genetic Characteristics of Recurrent and Metastatic Head and Neck Cancers

The ASCO Post  / October 25, 2016

Next-generation sequencing of recurrent or metastatic head and neck tumors at Memorial Sloan Kettering Cancer Center (MSK) has provided insight into the molecular characteristics of these tumors, which may aid in the implementation of precision treatment. Luc G. Morris, MD, MSc, of Memorial Sloan Ke...

Head and Neck Cancer

Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The ASCO Post  / October 25, 2016

As reported in the Journal of Clinical Oncology by Laura Q. Chow, MD, of the University of Washington, and colleagues, a fixed-dose reduced-frequency pembrolizumab (Keytruda) regimen produced durable responses in the phase IB KEYNOTE-012 expansion cohort of patients with recurrent or metastatic head...

Prostate Cancer

Similar Functional Outcomes With Robot-Assisted Laparoscopic and Open Radical Retropubic Prostatectomy

The ASCO Post  / October 25, 2016

Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar domain-specific quality-of-life or pathologic outcomes at 12 weeks in men with newly diagnosed, clinically localized prostate cancer, according to the results of a randomized phase III trial reported ...

Leukemia

Venetoclax Monotherapy Safe and Clinically Active in Acute Myelogenous Leukemia

The ASCO Post  / October 25, 2016

A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were repo...

Leukemia

Minimal Residual Disease Assessment and Prediction of Outcome in CLL Responders

The ASCO Post  / October 25, 2016

Assessment of minimal residual disease was associated with improved prediction of outcome in responders, as well as complete responders, in patients with chronic lymphocytic leukemia (CLL) who respond to treatment. Kovacs et al reported these findings, which are based on an analysis of two phase III...

Multiple Myeloma

Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma

The ASCO Post  / October 10, 2016

Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia Molecu...

Gynecologic Cancers

Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation

The ASCO Post  / October 10, 2016

In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer was...

Breast Cancer

Tailoring Breast Cancer Screening for Older Women by Breast Density and Risk

The ASCO Post  / October 10, 2016

A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density r...

Breast Cancer

Bevacizumab/Capecitabine vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

The ASCO Post  / October 10, 2016

As reported in The Lancet Oncology by Christoph Zielinski, MD, of the Medical University of Vienna and the Central European Cooperative Oncology Group, and colleagues, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine wa...

Bladder Cancer

High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder

The ASCO Post  / October 10, 2016

In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Seisen et al found that high-intensity local treatment was associated with an overall survival benefit in patients with metastatic urothelial carcinoma of the bladder. Quoc-Dien Trinh, MD, of Brigham and Women’s Ho...

Kidney Cancer

Extended Active Surveillance Prior to Systemic Therapy May Be Safe in Some Patients With Metastatic Renal Cell Carcinoma

The ASCO Post  / October 10, 2016

In a phase II trial reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found that some patients with metastatic renal cell carcinoma can safely undergo active surveillance for an extended duration prior to initiation of systemic thera...

Multiple Myeloma

Updated Outcomes, Impact of Age in Multiple Myeloma

The ASCO Post  / September 25, 2016

Updated Outcomes, Impact of Age in Multiple Myeloma As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone (...

Symptom Management

Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

The ASCO Post  / September 25, 2016

According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic co...

Skin Cancer

Combining Ipilimumab With Radiotherapy in Advanced Melanoma

The ASCO Post  / September 25, 2016

The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. ­Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues in...

Skin Cancer

Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma

The ASCO Post  / September 25, 2016

As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of the...

Issues in Oncology

Impact of Adherence to Cancer Prevention Guidelines on Diet, Physical Activity on Cancer Risk and Mortality

The ASCO Post  / September 10, 2016

According to the American Cancer Society’s 2016 Cancer Facts & Figures, behaviors such as poor diet choices, physical inactivity, excess alcohol consumption, and unhealthy body weight account for about 20% of all cancers diagnosed in the United States and likely could be prevented with lifestyle...

Breast Cancer

Cyclophosphamide/Methotrexate Maintenance Shows No Benefit in Hormone Receptor–Negative Breast Cancer, but Subgroup May Benefit

The ASCO Post  / September 10, 2016

Low-dose oral cyclophosphamide plus methotrexate maintenance therapy yielded no disease-free survival benefit in women with hormone receptor–negative early breast cancer, according to the phase III International Breast Cancer Study Group (IBCSG) 22-00 trial. Some evidence of benefit was observed in ...

Study Finds Wide Variation in Breast Density Assessments Among Radiologists

The ASCO Post  / September 10, 2016

A large observational study examining the variation in breast density assessment among radiologists in clinical practice has found a wide variation—from 6.3% to 84.5%—in the percentage of mammograms rated as showing dense breasts, which persisted after adjusting for patient characteristics. The find...

Gastrointestinal Cancer

Regorafenib Increases Progression-Free Survival in Advanced Gastric Cancer

The ASCO Post  / September 10, 2016

The multikinase inhibitor regorafenib (Stivarga) prolonged progression-free survival vs placebo in patients with previously treated advanced gastric carcinoma, in a phase II trial reported in the Journal of Clinical Oncology by Nick Pavlakis, MBBS, PhD, of the University of Sydney, Australia, and co...

Solid Tumors

Immune Cell Infiltrates May Portend Better Prognosis Across Several Tumor Types

The ASCO Post  / September 10, 2016

High expression of T-cell and B-cell signatures in infiltrates in the tumor microenvironment predicted improved overall survival across many tumor types, according to a study reported by Iglesia et al in the Journal of the National Cancer Institute. Benjamin Vincent, MD, of UNC (University of North ...

Issues in Oncology
Palliative Care

Hematologic Oncologists Surveyed on Quality Measures of End-of-Life Care

The ASCO Post  / September 10, 2016

In a study reported in the Journal of Clinical Oncology, Oreofe O. Odejide, MD, MPH, of Dana-Farber Cancer Institute, and colleagues surveyed hematologic oncologists to identify acceptable end-of-life-care quality measures and barriers to such care. Respondents considered unrealistic patient expecta...

Lung Cancer

Nivolumab in Recurrent Small Cell Lung Cancer

The ASCO Post  / August 25, 2016

In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the SCLC...

Lung Cancer

Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy

The ASCO Post  / August 25, 2016

Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori...

Lung Cancer

Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer

The ASCO Post  / August 25, 2016

Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...

Skin Cancer
Lung Cancer

Pembrolizumab for Untreated/Progressive Brain Metastases in Melanoma or NSCLC

The ASCO Post  / August 25, 2016

Sarah B. Goldberg, MD, of Yale University School of Medicine, and colleagues found that pembrolizumab (Keytruda) was active in untreated or progressive brain metastases in melanoma and non–small cell lung cancer (NSCLC), according to a single-center phase II trial reported in The Lancet Oncology. S...

Kidney Cancer

Final Results of METEOR Trial: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma

The ASCO Post  / August 10, 2016

As reported by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma t...

Kidney Cancer

Quality of Life With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma

The ASCO Post  / August 10, 2016

Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by David Cella, PhD, of Northwestern University, Chicago, et a...

Bladder Cancer

Anti–PD-L1 Antibody Durvalumab in Advanced Urothelial Bladder Cancer

The ASCO Post  / August 10, 2016

In a phase I/II study reported in the Journal of Clinical Oncology, Massard et al found that the anti–PD-L1 (programmed cell death ligand 1) antibody durvalumab was active in patients with previously treated advanced urothelial bladder cancer. Objective response appeared to be confined to patients w...

Lung Cancer

Low-Dose CT Screening: New Solid Nodules and Lung Cancer Probability

The ASCO Post  / August 10, 2016

As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated wit...

Skin Cancer

Ipilimumab Combined With Antigen-Specific Cytotoxic T Lymphocytes in Metastatic Melanoma

The ASCO Post  / August 10, 2016

In a study reported in the Journal of Clinical Oncology by Chapuis et al, concurrent use of cytotoxic T lymphocyte (CTL) antigen-4 (CTLA-4) blockade with ipilimumab (Yervoy) and adoptively transferred antigen-specific CTLs produced enduring responses in patients with stage IV melanoma. Cassian Yee, ...

Gynecologic Cancers

Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer

The ASCO Post  / August 10, 2016

According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Christian Kurzeder, MD, of Kliniken Essen-Mitte, Essen, Germany, et al found that adding pertuzumab (Perjeta) to investigator’s choice chemotherapy did not improve progression-free survival in women with...

Lung Cancer

Dabrafenib Plus Trametinib in BRAF V600E–Mutant Metastatic NSCLC

The ASCO Post  / August 10, 2016

In a phase II trial reported in The Lancet Oncology, Planchard et al found that combined MAPK pathway inhibition with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) resulted in a high response rate in patients with BRAF V600E–mutant non–small cell lung cancer (N...

Leukemia

Genomic Classification and Outcome in Acute Myeloid Leukemia

The ASCO Post  / July 25, 2016

As reported in The New England Journal of Medicine, Elli Papaemmanuil, PhD, of the Cancer Genome Project, Wellcome Trust Sanger Institute, and colleagues have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML Subg...

Breast Cancer

Mindfulness-Based Stress-Reduction Program May Reduce Psychological and Physical Symptoms in Breast Cancer Survivors

The ASCO Post  / July 25, 2016

A mindfulness-based stress-reduction program for breast cancer survivors was associated with psychological and physical symptom benefits during and at 6 weeks after intervention, according to a randomized trial reported in the Journal of Clinical Oncology by Cecile A. Lengacher, RN, PhD, of the Univ...

Lymphoma

No Apparent Benefit of GnRH in Preserving Ovarian Function and Fertility in Young Women With Lymphoma

The ASCO Post  / July 25, 2016

In a long-term follow-up of a European trial reported by Isabelle Demeestere, MD, PhD, of the Université Libre de Bruxelles in Belgium, and colleagues in the Journal of Clinical Oncology, gonadotropin-releasing hormone (GnRH) agonist treatment during chemotherapy in young women with lymphoma was not...

Issues in Oncology

Study Finds Poor Understanding of Illness in Patients With Advanced Cancer

The ASCO Post  / July 25, 2016

Few patients with advanced cancer and a short life expectancy have an accurate understanding of their illness, according to a study reported in the Journal of Clinical Oncology by Andrew S. Epstein, MD, of the Memorial Sloan Kettering Cancer Center, New York, and colleagues. The study involved 178 ...

Leukemia

Increased Risk for Cardiovascular Events Seen in Patients With CML Taking Tyrosine Kinase Inhibitors

The ASCO Post  / July 10, 2016

Although tyrosine kinase inhibitors have dramatically increased survival for patients with chronic myeloid leukemia (CML), continuous administration of these drugs may elicit long-term toxicity, including cardiovascular adverse events. To investigate the incidence of vascular events in patients with...

Colorectal Cancer

Norwegian Study Shows Benefit of Aspirin as Secondary Prevention in Patients With Colorectal Cancer

The ASCO Post  / July 10, 2016

A Norwegian population-based study reported in the Journal of Clinical Oncology by Simer J. Bains, MD, PhD, of the Centre for Molecular Medicine Norway, University of Oslo, and colleagues showed that use of aspirin after diagnosis of colorectal cancer was associated with improved colorectal cancer–s...

Gynecologic Cancers

Neoadjuvant Chemotherapy May Render Advanced Ovarian Cancers Responsive to Immunotherapy

The ASCO Post  / July 10, 2016

Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Frances R. Balkwill, PhD, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, United Kingdom, and colleagues publish...

CNS Cancers

Retroviral Replicating Vector That Delivers Cytosine Deaminase to Cancer Cells Active in Recurrent Glioblastoma

Charlotte Bath  / June 25, 2016

A phase I study by Timothy F. Cloughesy, MD, Director of the Neuro-Oncology Program at the UCLA Jonsson Comprehensive Cancer Center, and colleagues published in Science Translational Medicine investigated the effectiveness of vocimagene amiretrorepvec (Toca 511), an experimental nonlytic, retroviral...

Colorectal Cancer

Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer

Charlotte Bath  / June 25, 2016

In a French retrospective study reported by David Tougeron, MD, PhD, of Poitiers University Hospital, Poitiers, France, and colleagues in the Journal of the National Cancer Institute, the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with s...

Gastrointestinal Cancer

Increased Risk of Gallbladder Cancer May Be Associated With Consuming Large Amounts of Sweetened Beverages

Charlotte Bath  / June 25, 2016

A large prospective Swedish study reported by Susanna C. Larsson, PhD, of the Unit of Nutritional Epidemiology at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, Sweden, and colleagues found a 2.2-fold increased risk of gallbladder cancer in people who consumed two or ...

Hematologic Malignancies

Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease

Charlotte Bath  / June 25, 2016

In a study reported in the Journal of Clinical Oncology, Jeffrey Yu, MD, of the Indiana University School of Medicine, Indianapolis, and colleagues identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery C...

FOLFIRINOX in Locally Advanced Pancreatic Cancer

Matthew Stenger  / June 10, 2016

First-line FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin) is associated with median overall survival of approximately 2 years in patients with locally advanced pancreatic cancer, according to a systematic review and patient-level meta-analysis reported by Suker et al.1 Study Details...

Early Lapatinib-Related Rash in Breast Cancer

Matthew Stenger  / June 10, 2016

An analysis of the phase III adjuvant ALTTO trial showed that early rash was associated with better clinical outcome with lapatinib (Tykerb) treatment of HER2-positive breast cancer, as reported by Sonnenblick et al. It had been previously found that early rash was associated with improved pathologi...

International Prognostic Index for Chronic Lymphocytic Leukemia

Matthew Stenger  / June 10, 2016

The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an International Prognostic Index for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. The meta-anal...

Prostate Cancer
Geriatric Oncology

Significant Increased Risk of Noncancer Hospitalization Following Diagnosis of Prostate Cancer in the Elderly

Charlotte Bath  / May 25, 2016

Elderly men had a significant increase in the risk of noncancer hospitalizations following the diagnosis of prostate cancer, according to a population-based retrospective cohort study conducted by Amit D. Raval, PhD, and colleagues at West Virginia University, Morgantown. Results were published in t...

Breast Cancer

Improved Survival With Shorter Delays Between Diagnosis and Surgery and Before Initiating Adjuvant Chemotherapy

Charlotte Bath  / May 10, 2016

The survival benefits of reducing the time to surgery following a diagnosis of breast cancer and the time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a ...

Breast Cancer

Some Diagnostic Variability in Interpreting Breast Biopsy Slides

Charlotte Bath  / May 10, 2016

Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer patho...

Breast Cancer

Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women

Charlotte Bath  / May 10, 2016

The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase estrogen receptor–positive breast cancer ...

Palliative Care

Earlier Hospice Enrollment, Avoiding ICU Admissions, and Not Dying in the Hospital Associated With Perceptions of Better End-of-Life Care

Charlotte Bath  / April 25, 2016

Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,” according to a study in The...

Prostate Cancer

Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria

Charlotte Bath  / April 25, 2016

Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse event clusters in patients with advanced prostate cancer. The clusters “exp...

Skin Cancer

Most Patients With Melanoma Had Few Nevi, None Atypical

Charlotte Bath  / April 10, 2016

Although nevi are considered among the strongest risk factors for melanoma, most patients with melanoma had few total nevi and no atypical nevi, according to an analysis of 566 patients with invasive cutaneous melanoma. “Three notable findings emerged from this case study,” Alan C. Geller, MPH, RN, ...

Geriatric Oncology
Breast Cancer

Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older

Charlotte Bath  / April 10, 2016

A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was published in the Journal of Oncology Practice. The corresponding author o...

Colorectal Cancer

Fecal Immunochemical Test Highly Sensitive and Effective When Used for Colorectal Cancer Annual Screening Programs

Charlotte Bath  / March 25, 2016

Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing this test over four rounds of annual screening. “O...

Solid Tumors

High Rate of Overuse of Serum Tumor Marker Testing

Charlotte Bath  / March 25, 2016

A retrospective review to evaluate the frequency of serum tumor marker testing “found a high rate of serum tumor marker testing overuse and extreme overuse in patients with advanced solid tumors,” Melissa K. Accordino, MD, of Columbia University College of Physicians and Surgeons, New York, reported...

Colorectal Cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes

Charlotte Bath  / March 25, 2016

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment decis...

Hematologic Malignancies
Leukemia

Increasing the Dose of Obinutuzumab Monotherapy Raised the Response Rate

Charlotte Bath  / March 10, 2016

A randomized phase II study in symptomatic, untreated patients with chronic lymphocytic leukemia (CLL) found an increased overall response rate with obinutuzumab (Gazyva) at a 2,000 mg vs 1,000 dose. In addition, the “data demonstrate that obinutuzumab produces a higher response rate in symptomatic,...

Skin Cancer

Melanoma-Specific Survival Significantly Higher With Wider Excision Margins

Charlotte Bath  / March 10, 2016

Among patients with high-risk, primary cutaneous melanomas, the risk of death from melanoma, at a median follow-up of 8.8 years, was significantly higher among those randomized to surgery with a 1-cm excision margin than among those randomized to surgery with a 3-cm excision margin. Although overall...

Issues in Oncology

Cultural Awareness and Sensitivity Among Surgeons Do Not Always Result in Culturally Competent Care

Charlotte Bath  / March 10, 2016

A survey of oncology surgeons from six hospitals in Washington State found that the surgeons in the sample “displayed and valued cultural awareness and sensitivity” but that “cultural awareness and sensitivity did not necessarily result in culturally competent behavior.” These findings highlight the...

Colorectal Cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes

Charlotte Bath  / February 25, 2016

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment decis...

Solid Tumors

Increased Cancer Mortality Among Recipients of Solid-Organ Transplants

Charlotte Bath  / February 25, 2016

Solid-organ transplant recipients have a higher rate of cancer mortality than that expected in the general population, according to a Canadian study published in JAMA Oncology. Cancer mortality among transplant recipients “was significantly elevated compared with the Ontario population,” with a stan...

Prostate Cancer

Similar Low Incidence of Bowel Symptoms With Hypofractionated vs Conventionally Fractionated Radiotherapy in Localized Prostate Cancer

Matthew Stenger  / February 10, 2016

As reported by Wilkins et al in The Lancet Oncology, 2-year patient-reported outcomes in a UK phase III trial (CHHiP) substudy have shown a similar low incidence of bowel problems among patients with intermediate-risk localized prostate cancer receiving hypofractionated vs conventionally fractionate...

Head and Neck Cancer

No Benefit of Adding Adjuvant and Maintenance Lapatinib to Chemoradiation in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck

Matthew Stenger  / February 10, 2016

In a phase III trial reported in the Journal of Clinical Oncology, Harrington et al found that the addition of concurrent adjuvant lapatinib (Tykerb) to chemoradiation therapy and the use of maintenance lapatinib did not improve disease-free or overall survival in high-risk patients with resected sq...

Multiple Myeloma

Better Quality of Life With Melphalan and Prednisone Used With Lenalidomide Than With Thalidomide

Charlotte Bath  / December 25, 2015

A phase III Eastern Cooperative Oncology Group (ECOG) trial (E1A060) comparing melphalan, prednisone, and thalidomide (Thalomid) with melphalan, prednisone, and lenalidomide (Revlimid) in elderly patients with untreated multiple myeloma found that at the end of the induction period, patients receivi...

Gynecologic Cancers

Women Coinfected With Human Papillomavirus Had Reduced Risk for Invasive Cervical Cancer

Charlotte Bath  / December 25, 2015

Women co-infected with low-risk and high-risk human papillomavirus (HPV) had a reduced risk for invasive squamous cervical carcinoma and a longer time to progression than did women infected with high-risk human papillomavirus alone, according to a Swedish study published in the Journal of the Nation...

Lung Cancer
Palliative Care

‘Substantial Number’ of Patients Requiring Palliative Radiotherapy for Stage IV NSCLC Are Overtreated

Charlotte Bath  / December 25, 2015

An analysis of data from 46,803 patients with stage IV non–small cell lung cancer (NSCLC) who received palliative chest radiation therapy found that 49% received radiotherapy for longer than 15 fractions, and 28% received more than 25 fractions. This treatment pattern “is inconsistent with the resul...

Breast Cancer

Shift in Treatment Patterns of Ductal Carcinoma in Situ

Charlotte Bath  / December 10, 2015

An evaluation of national treatment trends for ductal carcinoma in situ from 1991 to 2010 and their impact on survival revealed “a substantial shift in locoregional treatment patterns for ductal carcinoma in situ,” Mathias Worni, MD, of Duke University Medical Center, Durham, North Carolina, and col...

Skin Cancer

Increased Risk of Second Nonmelanoma Skin Cancer Among Patients Receiving Immunosuppressive Therapy

Charlotte Bath  / December 10, 2015

Patients with rheumatoid arthritis treated with methotrexate had an increased risk of a second nonmelanoma skin cancer, and adding anti–tumor necrosis factor (TNF) may increase that risk, according to results of a retrospective cohort study reported in JAMA Dermatology. A similar association was see...

Prostate Cancer
Palliative Care

Aggressive End-of-Life Care More Frequent Among Black Men With End-Stage Prostate Cancer

Charlotte Bath  / November 25, 2015

A study to examine end-of-life care among black and white patients dying of prostate cancer found that “significant racial disparities in end-of-life care” do exist. “Although diagnostic and therapeutic interventions are less frequent in black patients with end-stage prostate cancer, the rate of hig...

Issues in Oncology

Falls Experienced by Older Patients Are Often Not Recorded or Responded to by Oncology Providers

Charlotte Bath  / November 25, 2015

A study comparing self-reported falls by older patients with cancer with the history and physical and/or clinic notes completed by their oncology providers “found that oncology providers rarely recorded or responded to falls in their older patients.” There was minimal evidence of documentation of fa...

Issues in Oncology

Increased Lifetime Risk of Developing Cancer in Patients With HIV

Charlotte Bath  / November 25, 2015

The effectiveness of antiretroviral therapy has enabled patients with HIV to live long enough to have high lifetime risks for several types of cancer. The finding has important clinical implications for cancer screening, as well as primary prevention, according to the results of a study funded by th...

Breast Cancer

Tamoxifen Use and Access to Fertility-Preservation Options Among Premenopausal Women With Breast Cancer

Charlotte Bath  / November 10, 2015

A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of tamoxifen. “Among patien...

Solid Tumors

Multiple Copies of TP53 Tumor-Suppressor Gene Potentially Related to Lower-Than-Expected Cancer Rate in Elephants

Charlotte Bath  / November 10, 2015

A lower-than-expected rate of cancer among elephants could be potentially related to multiple copies of TP53, “a crucial tumor suppressor gene mutated in the majority of human cancers,” according to a study published online by The Journal of the American Medical Association. “Compared with human cel...

Lung Cancer

Patients Whose Treatment Included Bevacizumab Were More Likely to Experience Toxicity but Less Likely to Be Hospitalized

Charlotte Bath  / October 25, 2015

A study among patients with advanced non–small cell lung cancer (NSCLC) treated with carboplatin-paclitaxel or carboplatin-paclitaxel-bevacizumab (Avastin) found that those receiving the triplet were more likely to experience a toxicity event but less likely to be hospitalized within 180 days after ...

Kidney Cancer

Patient Characteristics Differ in Some Clinical Trials From Real-World Population

Charlotte Bath  / October 25, 2015

Patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in real-world clinical practice tend to be older and sicker than the patients enrolled in pivotal clinical trials of these agents. In addition, patients with metastatic renal cell carcinoma treated with the mTOR in...

Breast Cancer

Diagnosis of Additional Small Cancers Suggests Screening Mammography Leads to Overdiagnosis

Charlotte Bath  / October 10, 2015

A study of screening mammography across U.S. counties found that “the clearest result of mammography screening is the diagnosis of additional small cancers” but without a “concomitant decline in the detection of larger cancers, which might explain the absence of any significant difference in the ove...

Prostate Cancer

Decreased Mortality in Men With Unfavorable-Risk Prostate Cancer and Moderate or Severe Comorbidities Treated With Radiotherapy Alone

Charlotte Bath  / October 10, 2015

Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in The Journal of the Am...

Lung Cancer

‘Encouraging Results’ With Newer EGFR TKIs in Patients With NSCLC Who Progressed After Prior EGFR TKI Therapy

Charlotte Bath  / September 25, 2015

Two studies of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among patients with non–small cell lung cancer (NSCLC) who had progressive disease following treatment with a first-generation EGFR tyrosine kinase inhibitor “show encouraging results,” according to an...

Leukemia

Azacitidine Increased Median Overall Survival Among Patients Aged 65 and Older With &gt; 30% Blasts

Charlotte Bath  / September 25, 2015

A multicenter, randomized, open-label, phase III trial among the difficult-to-treat population of patients aged aged 65 and older with acute myeloid leukemia (AML) with > 30% bone marrow blasts “showed that azacitidine was associated with a clinically meaningful improvement” in median overall sur...

Unneccessary Complexity in Scientific Terminology?

Charles P. Duvall, MD, MACP  / September 10, 2015

In the highlighted quote in the article titled “Ado-Trastuzumab Emtansine Fails to Replace Standard of Care in First-Line Metastatic Breast Cancer,” which appeared in on page 3 of the July 10 issue of The ASCO Post, a most remarkable sentence was constructed: T-DM1 and T-DM1 plus pertuzumab demonst...

Colorectal Cancer

Long-Term Use of Thyroid Hormone Replacement Linked to Decreased Risk of Colorectal Cancer

Charlotte Bath  / September 10, 2015

Long-term thyroid hormone replacement was associated with a decreased risk of colorectal cancer, but hyperthyroidism and untreated hypothyroidism were associated with a modestly elevated risk, according to a study using a large population-based medical records database from the United Kingdom. A to...

Lymphoma

Increased Lifetime Risk of Cardiovascular Disease for Patients Treated for Hodgkin Lymphoma

Charlotte Bath  / September 10, 2015

Survivors of Hodgkin lymphoma treated as adolescents or adults are at increased risk of cardiovascular diseases throughout their lives, according to results of a retrospective cohort study of 2,524 Dutch patients followed for a median of 20 years. “Treating physicians and patients should be aware of...

Issues in Oncology

Determining Why Patients With HIV Infection and Non–AIDS-Defining Cancers Are Less Likely to Receive Cancer Treatment

Charlotte Bath  / September 10, 2015

A survey sent to medical and radiation oncologists to identify factors contributing to observed disparities in cancer treatment between patients infected with HIV and those not infected “found that a substantial proportion of physicians (21%) would alter their treatment recommendations based on HIV ...

Hepatobiliary Cancer

More Than One-Third of Those Diagnosed With Hepatocellular Carcinoma as Outpatients Have Diagnostic Delays of 3 or More Months

Charlotte Bath  / September 10, 2015

Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Nishant Patel, MD, and colleagues concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a rev...

Issues in Oncology

Cancer Diagnosis Among Patients With Diabetes Reduced Adherence to Evidence-Based Medications

Charlotte Bath  / September 10, 2015

“A cancer diagnosis among patients with diabetes reduced adherence with evidence-based medications, particularly if patients’ life expectancy was short,” according to a study among Medicare beneficiaries reported in the Journal of Oncology Practice. “These findings emphasize the vulnerability of ind...

Colorectal Cancer

Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer

Charlotte Bath  / August 25, 2015

Collaboration between surgeons and medical oncologists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Tanvir ­Hussain, MD, MSc, and colleagues from Johns Hopkins University School of Medicine, Baltimore, and the Univers...

Colorectal Cancer

Statin Use Not Associated With Reduced Mortality Among Patients With Primary Colorectal Cancer

Charlotte Bath  / August 25, 2015

Statin use was not associated with reduced mortality among patients diagnosed with primary colorectal cancer between 2003 and 2009 and followed for a median of 3.4 years in the Darmkrebs: Chancen der Verhütung durch Screening (DACHS) study, an ongoing population-based study of colorectal cancer in s...

Colorectal Cancer

Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer

Charlotte Bath  / August 10, 2015

Collaboration between surgeons and medical oncologists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by ­Tanvir ­Hussain, MD, MSc, and colleagues from Johns Hopkins University School of Medicine, Baltimore, and the Univer...

Hepatobiliary Cancer

More Than One-Third of Those Diagnosed With Hepatocellular Carcinoma as Outpatients Have Diagnostic Delays of 3 or More Months

Charlotte Bath  / August 10, 2015

Nearly 20% of patients with hepatocellular carcinoma “wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth,” Nishant Patel, MD, and colleagues concluded in the Journal of the National Comprehensive Cancer Network. They based their conclusions on a rev...

Leukemia

Durable Responses at 3-Year Follow-up for CLL Patients Receiving Single-Agent Ibrutinib

Charlotte Bath  / July 25, 2015

At a median follow-up of 3 years, ibrutinib (Imbruvica) demonstrated continued activity with durable responses that improved in quality with extended treatment of patients with chronic lymphocytic leukemia (CLL). In addition, grade 3 toxicity and adverse events leading to treatment discontinuation d...

Thyroid Cancer

Thyroid Cancer Rarely Diagnosed in Those With Asymptomatic, Benign Nodules

Charlotte Bath  / July 25, 2015

A prospective, multicenter, observational study involving 992 consecutive patients with one to four asymptomatic, sonographically or cytologically benign thyroid nodules found that “the majority of nodules exhibited no significant size change during 5 years of follow-up or actually decreased in size...

Issues in Oncology

Significant Differences in Age at Diagnosis Between Blacks and Whites for Six Types of Cancer

Charlotte Bath  / July 10, 2015

Although blacks were diagnosed at a younger age than whites for nearly every cancer type, after adjustments for population structure shifted the comparisons toward older ages among blacks, only six statistically significant differences of 3 or more years remained, according to a study in the Journal...

Lung Cancer

Date of Last Chemotherapy Is Not a Proxy for Deciding When to Stop Treating Metastatic NSCLC

Charlotte Bath  / July 10, 2015

“Patients, their families, and oncologists recognize the administration of chemotherapy near death as aggressive and poor-quality care,” William F. Pirl, MD, MPH, and colleagues from Massachusetts General Hospital, Boston, wrote in the Journal of Oncology Practice. “However, rates have been slowly r...

Leukemia

Patients With Relapsed/Refractory CLL That Progresses Early on Ibrutinib Have Poor Outcomes

Charlotte Bath  / June 25, 2015

Most patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab (Rituxan), at Th...

Skin Cancer

Patients’ Desire for Rapid Notification of Skin Biopsy Results Leads to Preference for Phone Call Over Face-to-Face Visit

Charlotte Bath  / June 25, 2015

Patients’ preference for how they receive biopsy results “has shifted from face-to-face visit to discussion over the telephone because of a desire for rapid notification,” according to a survey of 301 patients recruited at three different melanoma clinics. Although 67.1% of the patients preferred to...

Response to May 10 Cartoon

Lynne Lederman, PhD  / June 25, 2015

As a medical writer specializing in oncology, an ASCO member, and someone who tries to build sensitivity to patients into all my work, I was concerned about the cartoon I saw in the May 10, 2015, issue of The ASCO Post. On page 46, there is a cartoon of someone being thrown off a cliff because he ha...

Leukemia

First-Line Imatinib With Early Switch to Nilotinib May Be Preferable to First-Line Use of More Potent Agents in CML

Charlotte Bath  / June 10, 2015

Using imatinib to treat chronic-phase chronic myeloid leukemia (CP-CML) first line, with selective switching to nilotinib (Tasigna) “leads to excellent molecular response and survival” and “may be preferable to universal first-line use of more potent agents, considering efficacy, toxicity, and econo...

Gastroesophageal Cancer

More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival

Charlotte Bath  / June 10, 2015

A population-based cohort study “indicates that more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” Maartje van der Schaaf, MD, PhD, of the Karolinska Institutet, Stockholm, and colleagues reported in the Journal of the National Cancer Institute. “Thes...

Article on Rare Cancer Generates Enthusiastic Response

The ASCO Post  / May 25, 2015

The article “Shining a Spotlight on Epithelioid Hemangioendothelioma,” written by Jane Gutkovich and published in the April 10, 2015, issue of The ASCO Post, generated an enthusiastic response from the patient and advocate community of individuals with this rare cancer. Here, we are pleased to share...

Breast Cancer

Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy

Charlotte Bath  / May 25, 2015

Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a study supported by the Ontario Institute of Cancer Research, Toronto. “In this population-based coho...

Lung Cancer

Prior Cancer Does Not Affect Outcomes Among Patients With Advanced Lung Cancer, Suggesting They Be Included in Clinical Trials

Charlotte Bath  / May 25, 2015

Analysis of data from 102,929 patients with stage IV lung cancer found that “prior cancer does not convey an adverse effect on clinical outcomes, regardless of prior cancer stage, type, or timing.” Based on these findings, investigators from the Harold C. Simmons Cancer Center, University of Texas S...

Lung Cancer

EGFR L858R Mutation in Blood Sample May Serve as Surrogate for Biopsy in Determining EGFR-Mutation Status

Charlotte Bath  / May 25, 2015

Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown that the EGFR L858R mutati...

Hepatobiliary Cancer
Supportive Care

Therapy for Hepatitis C Virus Infection in Patients With Cancer May Prevent Liver Disease Progression

Charlotte Bath  / May 25, 2015

“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers rev...

Issues in Oncology

People Living With HIV in the United States Have a 50% Excess Cancer Risk

Charlotte Bath  / May 25, 2015

The nearly 900,000 people in the United States living with diagnosed human immunodeficiency virus (HIV) infection have an excess cancer risk of 50%, according to a joint analysis of data by the National Cancer Institute and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, C...

Lung Cancer
Pancreatic Cancer
Geriatric Oncology

Chemotherapy Trial Results Overestimate Survival for Elderly Medicare Patients With Lung and Pancreatic Cancers

Charlotte Bath  / May 10, 2015

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Elizabeth B. Lamont, MD, MS, of Massachuset...

Multiple Myeloma
Geriatric Oncology

‘Frailty Profile’ Predicts Survival and Toxicities in Elderly Patients With Multiple Myeloma

Charlotte Bath  / May 10, 2015

A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician’s clinical ju...

Integrative Oncology
Palliative Care

Escalation of Oncology Services at End of Life May Be Moderated by Coordinated Care

Charlotte Bath  / May 10, 2015

“Use of oncology-related services is increasingly scrutinized, yet precisely which services are actually rendered to patients, particularly at the end of life, is unknown,” noted an article in the Journal of Oncology Practice. To address this knowledge gap, Eijean Wu, MD, of the Los Angeles County a...

Colorectal Cancer

Lower 30-Day Mortality, Increased Likelihood of Adjuvant Chemotherapy With Laparoscopic vs Open Colectomy for Stage III Colon Cancer

Charlotte Bath  / May 10, 2015

“In routine clinical practice, laparoscopic colectomy is associated with a lower 30-day mortality, shorter length of stay, and greater likelihood of adjuvant chemotherapy initiation among stage III colon cancer patients when compared with open colectomy,” according to an analysis of data from the Na...

Breast Cancer

Mammographic Density After Tamoxifen Initiation Linked to Improved Prognosis for Pre- and Postmenopausal Women With ER-Positive Breast Cancer

Charlotte Bath  / May 10, 2015

An improved prognosis for women with estrogen receptor (ER)-positive breast cancer who experience a large reduction in mammographic density following the initiation of tamoxifen treatment extends to premenopausal as well as postmenopausal women, researchers reported in the Journal of the National Ca...

Prostate Cancer

Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer

Charlotte Bath  / April 25, 2015

Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than the standard of care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and a...

Lymphoma

Risk Assessment for Hodgkin Lymphoma Evolving and Promises Greater Precision and Specific Clinical Relevance

Charlotte Bath  / April 25, 2015

“Risk assessment in Hodgkin lymphoma is continuously evolving and promises even greater precision and specific clinical relevance in the future,” Joseph M. Connors, MD, stated in Blood. Dr. Connors is Clinical Professor, British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of...

Lymphoma

Objective Response Rate of 44% Among Patients With Relapsed/Refractory DLBCL Receiving Brentuximab Vedotin

Charlotte Bath  / April 25, 2015

A phase II, open-label study evaluating the efficacy of brentuximab vedotin (Adcetris), an anti-CD antibody-drug conjugate, found that among 48 evaluable patients with CD30-positive diffuse large B-cell lymphoma (DLBCL), 21 (44%) had objective responses. These responses included 8 patients (17%) wit...

Skin Cancer
Cost of Care

Health and Economic Burden of Skin Cancer Substantial and Increasing, Highlighting the Value of Prevention Efforts

Charlotte Bath  / April 10, 2015

The average annual number of adults treated for skin cancer, both melanoma and nonmelanoma, in the United States increased from 3.4 million in 2002 to 2006 to 4.9 million in 2007 to 2011 (P < .001), according to a study published in the American Journal of Preventive Medicine. “During this perio...

Colorectal Cancer

Adding Aflibercept to FOLFIRI Resulted in Persistent Improvement in Overall Survival Over Time in Patients With Metastatic Disease

Charlotte Bath  / April 10, 2015

Patients with metastatic colorectal cancer showed a continued and persistent improvement in overall survival over time when they received the VEGF inhibitor aflibercept in addition to FOLFIRI (leucovorin, fluorouracil, irinotecan), according to a study reporting on the overall survival benefit and s...

Colorectal Cancer

Use of Minimally Invasive Colorectal Cancer Surgery Increases at NCCN Centers, but Wide Variation Exists

Charlotte Bath  / April 10, 2015

“Laparoscopic colectomy has been shown to have equivalent oncologic outcomes to open colectomy for the management of colon cancer, but its adoption nationally has been slow,” Heather Yeo, MD, of Memorial Sloan-Kettering Cancer Center in New York, and colleagues noted in reporting on a study investig...

Breast Cancer

Are Physicians Choosing Wisely When Imaging for Distant Metastases in Early-Stage Breast Cancer?

Charlotte Bath  / April 10, 2015

Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines—and a recommendation from ASCO—to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients wi...

Prostate Cancer

Targeted MR/Ultrasound Fusion–Guided Biopsy Increased Detection of  High-Risk Prostate Cancer

Charlotte Bath  / April 10, 2015

Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance (MR)/ultrasound fusion–guided biopsy was associated with an increased rate of detection of high-risk prostate cancer and a decreased rate of detection of low-risk prostate cancer than was standard extended-sextant...

Lymphoma

Radiotherapy in Good-Prognosis DLBCL

Theodore E. Yaeger, MD, FACR, FACRO, FRSM  / April 10, 2015

I was disturbed by the article on “Radiotherapy in Good-Prognosis ­DLBCL” published recently in The ASCO Post.1 As a practicing radiation oncologist for 30 years, I have seen the evolution of radiation techniques (and philosophy) for non-Hodgkin lymphoma progress from regional—or even systemic—dosi...

Prostate Cancer

Selenium Supplements After Diagnosis of Nonmetastatic Prostate Cancer May Raise Prostate Cancer Mortality Risk

Charlotte Bath  / March 25, 2015

“Selenium supplementation of 140 or more μg/d after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality,” according to a prospective study following 4,459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-up Study from...

Breast Cancer

Nearly Half of Women Taking Tamoxifen for Primary Prevention Discontinue Its Use Before 5 Years

Charlotte Bath  / March 25, 2015

After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued its use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister diagnosed with breast cancer but did not have breast cancer themselves. Eligible wom...

Pain Management

Key Evidence Gaps and Research Priorities Should Be Addressed So Physicians Can Identify Patients Most Likely to Benefit From Opioids

Charlotte Bath  / March 25, 2015

Key evidence gaps and research priorities must be addressed “so that physicians can recognize patients for whom opioids are most appropriate and use optimal regimens for these patients,” according to the National Institutes of Health (NIH) Pathways to Prevention Workshop final report on the role of ...

Gynecologic Cancers
Survivorship

High-Quality Diet Before Ovarian Cancer Diagnosis May Lengthen Survival

Charlotte Bath  / March 10, 2015

An overall high-quality diet at least 12 months before a diagnosis of ovarian cancer “was associated with a statistically significant 27% lower risk of death after ovarian cancer,” an analysis of dietary data from the Women’s Health Initiative showed. The protective effect was strongest among women ...

Colorectal Cancer

Racial Disparities in Survival Related More to Health Differences at Diagnosis Than to Subsequent Treatment

Charlotte Bath  / March 10, 2015

The persistent disparity in colon cancer survival by race seemed to be related more to differences in health at diagnosis than to differences in subsequent treatment, according to an analysis of data from the Survey, Epidemiology, and End Results (SEER)–Medicare database. “Our study suggests that th...

Supportive Care

Cutaneous Adverse Effects Associated With Tyrosine Kinase Inhibitors May Impact Quality of Life and Adherence to Treatment

Charlotte Bath  / March 10, 2015

Tyrosine kinase inhibitors “are associated with numerous adverse effects, many of which are cutaneous and can affect patients’ quality of life and impede their adherence to long-term treatment,” National Cancer Institute (NCI) investigators concluded after studying the adverse effects of the tyrosin...

Lung Cancer

First-Line Crizotinib Superior to Pemetrexed‑Plus‑Platinum Chemotherapy in Patients With ALK‑Positive NSCLC

Charlotte Bath  / February 25, 2015

Crizotinib (Xalkori) treatment “was superior to pemetrexed-plus-platinum chemotherapy with respect to progression-free survival, objective response rate, reduction in lung-cancer symptoms, and improvement in quality of life” in patients with previously untreated advanced anaplastic lymphoma kinase (...

Gastroesophageal Cancer
Survivorship

Primary Surgical Therapy Results in Higher 5-Year Survival for Patients With Advanced-Stage Disease

Charlotte Bath  / February 25, 2015

Bucking national trends toward preserving the larynx in patients with advanced laryngeal cancer, treatment of patients for stage IV disease at Louisiana State University (LSU) Health-Shreveport were more likely to involve primary surgical therapy, including total laryngectomy, and more likely to ach...

Colorectal Cancer

More on Ramucirumab in Metastatic Colorectal Cancer

Wafik S. El-Deiry, MD, PhD, FACP  / February 25, 2015

I am writing in regard to the report and commentary in this issue on the RAISE Trial. To begin, a discussion of this phase III clinical trial presented at the 2015 Gastrointestinal Cancers Symposium (RAISE study) may not be the most appropriate forum to air legitimate views on finances and operating...

Survivorship

More on Beating the Odds

Martha A. Tracy, MD  / February 25, 2015

Thank you very much for including Mr. Richard Heimler’s very rewarding story in The ASCO Post (“Beating the Odds,” December 1, 2014, page 118). It was a short, well-written example of excellent oncology management in the face of episodes of “terminal” lung cancer. His story was the perfect narrative...

CNS Cancers

Glioblastoma Clinical Trials

Adrienne C. Scheck, PhD  / February 25, 2015

I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open.   PHASE II Study Type: Phase...

Breast Cancer

Mammographically Dense Breasts Highly Prevalent Among American Women

Charlotte Bath  / February 10, 2015

A study on the prevalence of mammographically dense breasts in the United States “estimated that approximately 43% of women aged 40 to 74 years have heterogeneously or extremely dense breasts, corresponding to approximately 27.6 million U.S. women,” researchers reported in the Journal of the Nationa...

Skin Cancer

Adding Sargramostim to Ipilimumab Improved Overall Survival Among Patients With Unresectable Stage III or IV Melanoma

Charlotte Bath  / February 10, 2015

Patients with unresectable stage III or IV melanoma treated with ipilimumab (Yervoy) plus sargramostim (Leukine) had longer overall survival and less toxicity than did those treated with ipilimumab alone, according to a phase II randomized clinical trial conducted by the Eastern Cooperative Oncology...

Gastroesophageal Cancer

High Genetic Propensity to Obesity Raises Risk of Esophageal Adenocarcinoma

Charlotte Bath  / February 10, 2015

“People with a high genetic propensity to obesity have higher risks of esophageal metaplasia and neoplasia than people with a low genetic propensity,” according to analyses of data from the Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study. “These analyses provide the strongest ev...

Supportive Care
Sarcoma

Growing Support Group for Epithelioid Hemangioendothelioma Spins the ‘Wheel of Hope’

Jane Gutkovich  / February 10, 2015

Two years ago, my son was diagnosed with the rare vascular sarcoma epithelioid hemangioendothelioma, on which there is incredibly little reseach and knowledge (see here for more on this rare cancer). PubMed revealed a “characteristic” description: unpredictable behavior, no correlation with cytology...

Colorectal Cancer

AJCC Cancer Staging System Is Most Accurate Measuring Response to Chemoradiation in Locally Advanced Rectal Cancer

Charlotte Bath  / January 25, 2015

When classifying response to chemoradiation among patients with locally advanced rectal cancer, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (7th edition) system “is most accurate and should be adopted as the standard,” Attaphorn Trakarnsanga, MD, and colleagues at Memorial Sl...

Leukemia

Patients With Chronic Lymphocytic Leukemia Who Progress After Front-line Treatment May Be Candidates for Novel Noncytotoxic Therapies

Charlotte Bath  / January 25, 2015

Although patients who relapse within 3 years of front-line fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) therapy have poor survival when treated with conventional salvage regimens, these patients may be candidates for novel noncytotoxic therapies, according to an analysis of extended r...

CNS Cancers

Ten Best-Practice Measures Improve Quality of Care During Perioperative Period for Patients With Glioma

Charlotte Bath  / January 25, 2015

Ten best-practice measures identified by a multidisciplinary team at the Norris Cotton Cancer Center (NCCC) at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, were used to improve the care provided to patients with glioma during the perioperative period. “Using a plan-do-study-act ...

Breast Cancer

About 25% of Patients Who Undergo Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery

Charlotte Bath  / January 25, 2015

“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online by JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility factors,” reported Lee ...

Breast Cancer

Mammographic Density Is Highly Heritable, Possibly Explaining the Familial Aggregation of Breast Cancer

Charlotte Bath  / January 25, 2015

Using a fully automated method to ascertain volumetric mammographic density, a study conducted by the Karolinska Mammography (KARMA) project for risk prediction of breast cancer in Sweden confirmed the high heritability of mammographic density, although estimates were weaker for absolute than for pe...

Leukemia

Obinutuzumab May Have Synergistic Action With New Tyrosine Kinase Inhibitors

Charlotte Bath  / December 15, 2014

Final results from the phase I/II GAUGUIN study showed that obinutuzumab (Gazyva) monotherapy was active in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia, European researchers reported in Blood. In phase II, median progression-free survival was 10.7 months, and...

Colorectal Cancer

Patients With Metastatic Colorectal Cancer Have Improved Outcome With FOLFOXIRI and Bevacizumab

Charlotte Bath  / December 15, 2014

Patients with untreated metastatic colorectal cancer who received ­FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, irintotecan) plus bevacizumab (Avastin) had improved survival compared with patients who received FOLFIRI (folinic acid, fluorouracil, irintotecan) plus bevacizumab in a phase III r...

Colorectal Cancer

Small Risk-Adjusted Variation in Hospital Readmissions Following Colorectal Cancer Surgery

Charlotte Bath  / December 15, 2014

“Little risk-adjusted variation exists in hospital readmission rates after colorectal surgery,” according to an analysis of data from 44,822 patients who underwent colorectal resection for cancer at 1,401 U.S. hospitals between 1997 and 2002. “The use of readmission rates as a high-stakes quality me...

Colorectal Cancer

Personalized Genetic and Environmental Risk Assessment Does Not Increase Use of Colorectal Cancer Screening

Charlotte Bath  / December 15, 2014

Individualized genetic and environmental risk assessment of susceptibility to colorectal cancer does not influence adherence to screening in average-risk persons, according to results from a two-group, randomized, controlled trial. Among patients who received genetic and environmental risk assessmen...

Issues in Oncology

Over 14 Million Major Medical Conditions in U.S. Adults Linked to Cigarette Smoking

Charlotte Bath  / December 1, 2014

At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers, prevalence ratios w...

Gastroesophageal Cancer

Customizing Surveillance Strategy in Patients With Esophageal Adenocarcinoma

Charlotte Bath  / December 1, 2014

A surveillance strategy for patients with esophageal adenocarcinoma treated with chemoradiation and surgery (trimodality therapy) can potentially be customized based on surgical pathology stage, according to an analysis of 518 patients with esophageal adenocarcinoma who underwent trimodality therapy...

Lymphoma

Second-Line Gemcitabine the Preferred Option for Relapsed or Refractory Lymphoma

Charlotte Bath  / December 1, 2014

For patients with relapsed or refractory aggressive lymphoma in a National Cancer Institute of Canada clinical trial, second-line treatment with GDP (gemcitabine, dexamethasone, and cisplatin) was as effective as DHAP (dexamethasone, cytarabine, and cisplatin). Treatment with GDP “can be considered ...

Lymphoma

Risk of Premature Menopause Raised by Some but Not All Hodgkin Lymphoma Therapies

Charlotte Bath  / December 1, 2014

An analysis of nonsurgical menopause risk among 2,127 women treated for Hodgkin lymphoma found that “risk of premature menopause increased more than 20-fold” after ovarian radiotherapy, alkylating chemotherapy other than dacarbazine, or BEAM (carmustine [BiCNU], etoposide, cytarabine, melphalan) che...

Pain Management

Unique Barriers to Pain Control

Khalid L. Rehman, MD, FACP, MPA  / December 1, 2014

I read with great interest your interview with Virginia LeBaron, PhD, APRN, about barriers to adequate pain control (“Despite Growing Awareness, the Global Crisis of Untreated Cancer Pain Persists,” The ASCO Post, October 15, 2014). Having served as the medical director of a hospice, I am passionat...

Raising Consciousness About Drug Costs: A Call to Action

William S. Shimp, MD  / December 1, 2014

As medical oncologists working in chemotherapy utilization management (Oncology Analytics, Inc), my colleagues and I find ourselves daily in the center of the drug-cost maelstrom. While it is encouraging to see that more attention is being paid in the popular and medical press to this “unsustainable...

Breast Cancer

Neoadjuvant Chemotherapy Plus Two Anti-HER2 Agents Optimal for HER2-Positive Breast Cancer

Charlotte Bath  / November 15, 2014

For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The st...

Gynecologic Cancers

Cervical Cancer Risks After Negative HPV Test Lower at 3 Years Than After Negative Pap Result

Charlotte Bath  / November 1, 2014

Three-year risks for cervical cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were lower following a negative test for human papillomavirus (HPV) than following a negative Pap test, according to a large study comparing three cervical cancer screening strategies, HPV or Pap tes...

Pancreatic Cancer

Vitamin D Deficiency Is Prevalent Among Patients With Advanced Pancreatic Cancer

Charlotte Bath  / November 1, 2014

Vitamin D deficiency was highly prevalent among patients newly diagnosed with advanced pancreatic cancer, and black patients had statistically significantly lower levels than white patients, according to a recent study reported by Katherine Van Loon, MD, MPH, of the UCSF Helen Diller Family Comprehe...

Multiple Myeloma
Geriatric Oncology

Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients

Charlotte Bath  / November 1, 2014

Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with bortezomib/...

Leukemia

Obinutuzumab Could Have Synergistic Action With New Tyrosine Kinase Inhibitors

Charlotte Bath  / November 1, 2014

Final results from the phase I/II GAUGUIN study showed that obinutuzumab (Gazyva) monotherapy was active in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia, European researchers reported in Blood. In phase II, median progression-free survival was 10.7 months and ...

Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Prostate Cancer

Overscreening for Prostate, Breast, Colorectal, and Cervical Cancer Can Raise Costs and Harm Patients

Charlotte Bath  / October 15, 2014

Analyses of data from 27,404 people aged 65 and older participating in the National Health Interview Survey (NHIS) from 2000 through 2010 suggest that overscreening for prostate, breast, cervical, and colorectal cancer screening “is common in both men and women, which not only increases health care ...

Colorectal Cancer

Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer

Charlotte Bath  / October 15, 2014

The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who progressed on oxaliplatin-based chemotherapy persisted beyond median survival times for ...

Breast Cancer

Comorbidity Associated With Shorter Overall Survival but Not With Time to Relapse or Toxicity in Older Women on Adjuvant Chemotherapy

Charlotte Bath  / October 15, 2014

In the Cancer and Leukemia Group B (CALGB) 70103 study, comorbidity was associated with shorter overall survival among older women with early-stage breast cancer and good functional status receiving adjuvant chemotherapy. “The presence of four or more conditions appeared to be a threshold for shorte...

Breast Cancer

Patients With DCIS Have Decreased Risk of Cardiovascular Death, Independent of Treatment

Charlotte Bath  / October 15, 2014

Recent concerns about potential overdiagnosis and overtreatment of ductal carcinoma in situ of the breast (DCIS) led researchers in the Netherlands to study late effects of treatment, such as cardiovascular disease, morbidity, and mortality in a large population-based cohort of DCIS patients. “After...

Lung Cancer

FDG-PET Is Less Specific in Diagnosing Lung Cancer in Areas With Endemic Infectious Lung Disease

Charlotte Bath  / October 15, 2014

Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An analysi...

Lymphoma

Pro-oxidant Molecule Imexon Shows Clinical Activity in Relapsed/Refractory B-Cell NHL

Charlotte Bath  / September 15, 2014

The pro-oxidant molecule imexon (Amplimexon/NSC-714597) produced an overall response rate of 30% in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) participating in a phase II study. Noting that “lymphoma cells are subject to higher levels of oxidative stress than their normal co...

Breast Cancer

Most Women Who Choose Breast Reconstruction Are Satisfied With Decision-Making Process

Charlotte Bath  / September 15, 2014

Most patients who choose to have breast reconstruction following mastectomy are satisfied with the decision-making process. Reasons for not choosing reconstruction vary by race and include the desire to avoid additional surgery and fear of implants. These and other conclusions of an analysis of wome...

Lung Cancer

No Survival Benefits With Erlotinib and Whole-Brain Radiotherapy for NSCLC With Multiple Brain Metastases

Charlotte Bath  / September 15, 2014

“To exploit the potential radiosensitizing properties, the direct effect on brain metastases, and systemic activity of erlotinib,” researchers from the United Kingdom tested concurrent erlotinib and whole-brain radiotherapy followed by maintenance erlotinib in patients with of non–small cell lung ca...

Colorectal Cancer

Substantial Reductions in Surgical Site Infections After Colorectal Surgery With Bundling Approach

Charlotte Bath  / September 15, 2014

Use of a preventive surgical site infection bundle that spanned the phases or perioperative care “was associated with a substantial reduction in [surgical site infections] after colorectal surgery,” according to results of a retrospective study of 559 patients who underwent major elective colorectal...

Leukemia
Lymphoma

Allogeneic Conditioning Regimen Reduces Myelosuppression, Graft-vs-Host Disease in Lymphocytic Leukemia/Lymphoma

Charlotte Bath  / September 15, 2014

The combination of bendamustine (Treanda), fludarabine, and rituximab (Rituxan), or BFR, was shown to be safe and effective conditioning for patients with relapsed chronic lymphocytic leukemia/lymphoma receiving allogeneic stem cell transplantation from related or unrelated donors. “Remarkably, this...

Lymphoma

Para-Aortic Lymph Node Radiation Raises Risk of Developing Diabetes Mellitus in Hodgkin Lymphoma Survivors

Charlotte Bath  / September 15, 2014

Radiation to the para-aortic lymph nodes, “leading to radiation exposure of the pancreas, is associated with a dose-dependent increased risk” of developing diabetes mellitus among long-term survivors of Hodgkin lymphoma (HL), according to a study by Frederika A. van Nimwegen, MSc, of the Netherland...

Prolonged TV Viewing, Other Sedentary Behaviors Linked to Increased Risk of Particular Cancers

Charlotte Bath  / September 1, 2014

“Prolonged TV viewing and time spent in other sedentary pursuits is associated with increased risks of certain types of cancer,” concluded a meta-analysis of data from 43 observational studies including more than 4 million people and 68,936 cancer cases. A positive association with overall sedentary...

Colorectal Cancer

Patient, Tumor Characteristics Associated With BRAF and KRAS Mutations

Charlotte Bath  / September 1, 2014

KRAS and BRAF V600E mutations were nearly mutually exclusive and associated with specific patient and tumor characteristics, such as age and smoking status, according to an analysis of data from the N0147 phase III trial for stage III colon cancer. Primary tumors were assessed for KRAS and BRAF V60...

Skin Cancer

Simple Bedside Assessment of Pain and Itch Is Valuable Tool for the Evaluation of Suspicious Skin Lesions

Charlotte Bath  / September 1, 2014

A prospective, clinicopathologic study involving 268 patients with biopsy-proven basal cell carcinoma, squamous cell carcinoma, malignant melanoma, or melanoma in situ “revealed that pain is associated with histologic features that involve deeper dermal processes in [squamous cell carcinoma] lesions...

Lymphoma

First Prospective Study of Rare Lymphoma Shows Promising but Inconclusive Results With DA-EPOCH-R

Charlotte Bath  / September 1, 2014

Presenting “the first prospective study” of mediastinal gray zone lymphoma, researchers from the National Cancer Institute reported that DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan) and filgrastim (Neupogen) i...

Breast Cancer

Less Than 1% Absolute Survival Benefit at 20 Years Found for Contralateral Prophylactic Mastectomy

Charlotte Bath  / August 15, 2014

Theorizing that an exaggerated perceived benefit from contralateral prophylactic mastectomy may have led to the substantial increase in its use in recent years, researchers from the University of Minnesota in Minneapolis used a Markov simulated decision-analytic model to evaluate the magnitude of th...

Lung Cancer

Selected Patients With Lung Cancer and Poor Performance Status May Benefit From Standard Therapy

Charlotte Bath  / August 15, 2014

Patients with poor performance status have an increased incidence of adverse effects from therapy and worse overall outcomes than those with good performance status, but “a selected proportion may still benefit from standard therapy,” according to a review article published in the Journal of the Nat...

Colorectal Cancer

High False-Positive Rate of Elevated CEA Seen in Patients With Resected Colorectal Cancer

Charlotte Bath  / August 15, 2014

A retrospective study finding a 49% false-positive of carcinoembryonic antigen (CEA) testing among patients with a history of resected colorectal cancer, “suggests that confirmation of an ongoing increase in CEA level should be universal practice before an extensive workup is initiated,” Anya Litvak...

Hepatobiliary Cancer

Everolimus Did Not Improve Survival in Hepatocellular Cancer After Progression on Sorafenib

Charlotte Bath  / August 15, 2014

“Despite the strong scientific rationale and preclinical data, everolimus [Afinitor] plus best supportive care failed to improve survival over placebo plus best supportive care” among patients with advanced hepatocellular cancer that progressed during or after receiving sorafenib (Nexavar), or who w...

Head and Neck Cancer

Identifying and Managing Distress in Patients With Head and Neck Cancers

Charlotte Bath  / August 15, 2014

A quality improvement initiative at the Norris Cotton Cancer Center in Lebanon, New Hampshire, resulted in biweekly screening rates for psychological distress among patients treated at the head and neck medical oncology clinic increasing from 0% to 74% within a 2-year period. “Distress screening als...

Multiple Myeloma

Higher-Dose Carfilzomib Produces ‘Remarkable’ Response Duration in Relapsed/Refractory Multiple Myeloma

Charlotte Bath  / August 15, 2014

Higher-dose carflizomib (Kyprolis) “provided a high overall response rate with a remarkable duration of response in patients with relapsed or refractory multiple myeloma” in a phase II study, Nikoletta Lendvai, MD, PhD, and colleagues from Memorial Sloan Kettering Center, New York, wrote in Blood. O...

What Do Humans and Laboratory Rats Have in Common?

The ASCO Post  / August 15, 2014

The requirements for sound evidence of a drug’s therapeutic benefit have translated laboratory experience to human testing. In the laboratory, experimental animals give their lives to lethal testing of drugs and scientific analysis. LD50, the terminology denoting an anticipated 50% death rate of lab...

Breast Cancer

Women With Small, Node-Negative Breast Tumors Have Excellent Prognosis Without Chemotherapy 

Charlotte Bath  / July 25, 2014

Women who have small (≤ 1 cm), node-negative breast tumors “have an excellent prognosis without chemotherapy,” concluded the authors of a prospective cohort study involving 4,113 women with T1a,b, N0, M0 breast cancer. “Size and tumor subtype may identify patients in whom the rate of recurrence just...

Colorectal Cancer
Survivorship

Colorectal Cancer Survivors Prefer More Information on Late Effects of Treatment and Recurrence Risks

Charlotte Bath  / July 25, 2014

Survivors of nonmetastatic colorectal cancer, when surveyed about their needs and preferences for survivorship information, responded that they would prefer receiving more information about late effects of treatment, challenges to expect, general health maintenance, and risks of recurrence. Most of ...

Multiple Myeloma

High Response Rate and Good Safety Profile for Carfilzomib Plus Cyclophosphamide and Dexamethasone

Charlotte Bath  / July 25, 2014

A multicenter, open-label phase II trial found that the selective proteasome inhibitor carfilzomib (Kyprolis), in combination with cyclophosphamide and dexamethasone produced high complete response rates and was associated with low toxicity in patients with newly diagnosed multiple myeloma. “Respons...

Breast Cancer

Underuse of Trimodality Treatment for Patients With Inflammatory Breast Cancer Negatively Impacts Survival

Charlotte Bath  / July 10, 2014

Analysis of data for 10,197 women treated for nonmetastatic inflammatory breast cancer treated over a 12-year-period found that the use of trimodality treatment (chemotherapy, surgery, and radiation therapy) fluctuated annually between 58.4% and 73%. “Underutilization of trimodality therapy negative...

Head and Neck Cancer
Issues in Oncology

Limited Public Awareness of Head and Neck Cancers Raises Concerns About Prevention and Detection

Charlotte Bath  / July 10, 2014

Public awareness of head and neck cancer is limited, with the lack of awareness including the term head and neck cancer and common symptoms and risk factors, such as tobacco use and human papillomavirus (HPV), according to results of a cross-sectional online survey reported in JAMA Otolaryngology-He...

Skin Cancer

Modest Improvement in Progression-Free but Not Overall Survival With Selumetinib vs Chemotherapy

Charlotte Bath  / July 10, 2014

Patients with uveal melanoma treated with selumetinib had modestly improved progression-free survival and response rate compared to patients treated with chemotherapy, but no improvement in overall survival, according to results of a randomized, open-label, phase II trial. “Improvement in clinical o...

Colorectal Cancer
Geriatric Oncology

Colorectal Cancer Screening Recommended Past Age 75 for Previously Unscreened Patients

Charlotte Bath  / June 25, 2014

Colorectal cancer screening is cost-effective and “should be considered well beyond age 75 years” for individuals not previously screened, according to a computer simulation study published in the Annals of Internal Medicine. The researchers noted that while the U.S. Preventive Services Task Force ...

Breast Cancer

Long-Term Follow-up Confirms Low Incidence of Cardiac Events Associated With Trastuzumab

Charlotte Bath  / June 25, 2014

At a median follow-up of 8 years, patients receiving trastuzumab (Herceptin) sequentially after chemotherapy and radiotherapy in the Herceptin Adjuvant (HERA) trial had a low incidence of cardiac events and these were reversible in the vast majority of patients. This long-term assessment confirms an...

Lung Cancer
Palliative Care

Increased Hospice Use Among Minority Patients Treated in Provider-Based Research Networks

Charlotte Bath  / June 10, 2014

Minority patients with lung cancer who receive treatment in practices affiliated with provider-based research networks “have greater hospice enrollment than those treated in academic and community practices,” concluded Dolly C. Penn, MD, MSCR, and colleagues at the University of North Carolina Schoo...

Supportive Care

Cancer Patients at High Recurrence Risk for Venous Thromboembolism Should Be Considered for Secondary Prophylaxis

Charlotte Bath  / June 10, 2014

The risk of recurrence of venous thromboembolism in cancer patients can be stratified. “In particular, patients with brain, lung, stage IV pancreatic or ovarian cancer, myeloproliferative or myelodysplastic disorders, [other] stage IV cancer, cancer stage progression or leg paresis have the highest ...

Issues in Oncology
Supportive Care

For Hospitalized Cancer Patients, Thromboprophylaxis Often Prescribed Without Regard to Risk Factors

Charlotte Bath  / June 10, 2014

Pharmacologic thromboprophylaxis is commonly prescribed to hospitalized patients with cancer without regard to concomitant risk factors for venous thromboembolism, according to a prospective, cross-sectional study of patients with cancer at five academic medical centers. Results were reported in the...

Prostate Cancer

Genitourinary Toxicity More Likely With Stereotactic Body Radiotherapy Than With Intensity-Modulated Radiotherapy

Charlotte Bath  / May 15, 2014

A retrospective analysis of patients with prostate cancer receiving primary treatment with either stereotactic body radiation therapy or intensity-modulated radiation therapy found that those receiving stereotactic body radiotherapy had greater rates of genitourinary toxicity during 2-year follow-up...

Prostate Cancer

Tadalafil Did Not Prevent Erectile Dysfunction Among Men Receiving Radiotherapy

Charlotte Bath  / May 15, 2014

Daily use of tadalafil (Cialis) did not improve erectile function compared to placebo or prevent erectile dysfunction among men undergoing radiotherapy for prostate cancer, according to results of a stratified, placebo-controlled, double-blind, parallel-group study with 1:1 randomization at 76 commu...

Breast Cancer

Adjuvant Chemotherapy Accelerates Pace of Physiologic Aging in Women Treated for Breast Cancer

Charlotte Bath  / May 15, 2014

“Adjuvant chemotherapy for breast cancer is gerontogenic,” accelerating the pace of physiologic aging, according to an analysis of blood and clinical data from 33 women with stage I to III breast cancer. “We have shown that cytotoxic chemotherapy potently induces the expression of markers of cellula...

Issues in Oncology

Food and Drug Interactions Could Reduce Effectiveness of Oral Chemotherapy

Charlotte Bath  / May 15, 2014

Oral chemotherapy agents are associated with drug and food interactions that can significantly reduce the effectiveness of oral chemotherapy and possibly result in harm to patients, according to a study in the Journal of Oncology Practice. It is important therefore, according to the study’s authors,...

Breast Cancer

Exemestane to Reduce Invasive Breast Cancer Risk Has Small Negative Impact on Quality of Life

Charlotte Bath  / May 1, 2014

Detailed quality-of-life data from the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Mammary Prevention 3 (MAP.3) trial showed that exemestane given for the prevention of breast cancer “has limited negative impact on menopause-specific and health-related [quality of life] in h...

Gynecologic Cancers

Desensitization Protocols May Allow Reintroduction of Chemotherapeutic Agents After Hypersensitivity Reactions

Charlotte Bath  / May 1, 2014

Hypersensitivity reactions to chemotherapeutic agents used to treat ovarian cancer are “increasingly common and can greatly limit their use,” according to an article published in the Journal of the National Comprehensive Cancer Network. “Drug desensitization has emerged as a safe and effective way o...

Lymphoma

Brentuximab Vedotin Shows Antitumor Activity in Patients With Relapsed Peripheral T-Cell Lymphoma

Charlotte Bath  / May 1, 2014

In a phase II study, the 34 evaluable patients with peripheral T-cell lymphomas who received brentuximab vedotin (Adcetris) had an overall response rate of 41%, including an overall response rate of 54% among the 13 patients with angioimmunoblastic T-cell lymphoma. The median progression-free surviv...

Survivorship

Identifying One Main Provider and Involving Oncology Specialist Are Key to High-Quality Rating for Follow-up Care

Charlotte Bath  / May 1, 2014

Long-term cancer survivors are more likely to rate their follow-up care as high-quality when one main provider is identified and an oncology specialist is involved, according to results of a population-based cross-sectional study among adult survivors of breast, prostate, colorectal, endometrial, an...

Breast Cancer

Breast Reconstruction Has Increased Over Time but Varies Widely by Region

Charlotte Bath  / April 15, 2014

Analysis of data from 20,560 women undergoing mastectomy for breast cancer found that breast reconstruction use “increased from 46% in 1998 to 63% in 2007 (P< .001), with increased use of implants and decreased use of autologous techniques over time (P < .001),” according to a report published...

Leukemia

Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase Chronic Myeloid Leukemia

Charlotte Bath  / April 15, 2014

Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to long-term results of a randomized phase III study. The CA180-034 study also found that early molecular and c...

Leukemia

Adding Idelalisib to Rituximab Improved Survival in Patients With Relapsed CLL

Charlotte Bath  / April 15, 2014

Receiving rituximab (Rituxan) with idelalisib, rather than rituximab with placebo, “significantly improved progression-free survival, response rate, and overall survival” among patients with relapsed chronic lymphocytic leukemia (CLL) who were less able to undergo chemotherapy because of clinically ...

Lymphoma

Bendamustine/Rituximab May Be Important Alternative for Indolent NHL or MCL

Charlotte Bath  / April 15, 2014

Results from the BRIGHT study combined with long-term safety data from other studies suggest that bendamustine (Treanda) plus rituximab (Rituxan) “may be an important alternative treatment option” for the initial treatment of patients with low-grade non-Hodgkin lymphoma (NHL) and mantle cell lymphom...

Colorectal Cancer

For Metastatic Colorectal Cancer, Bevacizumab Is More Commonly Included Than Anti-EGFR Antibody Therapies

Charlotte Bath  / March 15, 2014

Analysis of a large cohort of patients with metastatic colorectal cancer who received chemotherapy at academic, private, and community-based oncology practices using the same chemotherapy order entry system showed that “bevacizumab has been more consistently integrated into treatment regimens than a...

Gynecologic Cancers

Aspirin Associated With Reduced Risk of Ovarian Cancer, Especially in Low Daily Doses

Charlotte Bath  / March 15, 2014

“Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin,” according to an analysis of pooled individual data from the Ovarian Cancer Association Consortium. Analyzing data from 12 population-based case-control studies of ovarian cancer, wit...

Prostate Cancer

Dietary Lycopene Linked to Reduced Risk of Lethal Prostate Cancer, Less Tumor Angiogenesis

Charlotte Bath  / March 15, 2014

“Dietary intake of lycopene was associated with reduced risk of lethal prostate cancer and with a lesser degree of angiogenesis in the tumor,” Ke Zu, MD, of Harvard School of Public Health, Boston, and colleagues concluded after reviewing dietary information and total and lethal prostate cancer case...

Thyroid Cancer

‘Epidemic of Diagnosis’ of Thyroid Cancer Is Most Acute for Women

Charlotte Bath  / March 15, 2014

The epidemiology of the increased incidence of thyroid cancer, which has nearly tripled since 1975, “suggests that it is not an epidemic of disease but rather an epidemic of diagnosis,” Louise Davies, MD, MS, and H. Gilbert Welch, MD, MPH, concluded after analyzing trends in patients diagnosed with ...

Issues in Oncology

Task Force Recommends Against Beta-Carotene or Vitamin E Supplements for Primary Cancer Prevention

Charlotte Bath  / March 15, 2014

The U.S. Preventive Services Task Force (USPSTF) recommends against the use of beta-carotene or vitamin E supplementation for the primary prevention of cancer or cardiovascular disease, according to an updated recommendation statement published in the Annals of Internal Medicine. “The USPSTF found a...

Issues in Oncology

Cancer Genes and Molecular Medicine: More Education Needed

Jeff Boyd, PhD  / March 15, 2014

I read with interest and concern the Perspective piece, “Cancer Genes, Promiscuity, and the National Debt,” which appeared on page 1 of the February 1st issue of The ASCO Post. The underlying premise of this wide-ranging and provocative article would appear to be that in a rush to implement “genomic...

The Author Replies

Derek Raghavan, MD, PhD, FACP, FRACP, FASCO  / March 15, 2014

I read with interest the note from Jeff Boyd, PhD, Senior Vice-President for Molecular Medicine at Fox Chase Cancer Center, calling into question my recent commentary about the high costs of partly validated testing in the domain of molecular medicine. One of the oldest tricks in the book is to call...

Issues in Oncology

After Next-Generation Sequencing: Guiding Patients to the Right Treatment

John Jakob, MD PhD  / March 15, 2014

In the near future, community oncologists will be tasked with helping patients interpret the results of next-generation sequencing of their tumors. Specifically, we will help patients choose an academic center with a phase I targeted therapy program that is a plausible fit for their disease. Unfort...

Lung Cancer

Nintedanib Combined With Docetaxel Is Effective Second-Line Option for Advanced NSCLC

Charlotte Bath  / March 1, 2014

The combination of nintedanib and docetaxel “is an effective second-line option” for patients with advanced non–small cell lung cancer (NSCLC) who have received previous treatment with one line of platinum-based therapy, according to results from the phase III LUME-Lung 1 study published in The Lanc...

Lymphoma

R-GCVP Regimen for Patients With Diffuse Large B-Cell Lymphoma and Cardiac Comorbidity

Charlotte Bath  / March 1, 2014

For patients with diffuse large B-cell lymphoma (DLBCL) who are unable to receive anthracycline-containing chemoimmunotherapy because of cardiac comorbidity, a regimen of rituximab (Rituxan), gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) “is an active, reasonably well-tolerat...

Pancreatic Cancer

High Expression of hENT1 Can Predict Better Survival Among Patients on Postsurgical Gemcitabine

Charlotte Bath  / February 15, 2014

High levels of expression of the human equilibrative nucleoside transporter 1 (hENT1) were associated with longer median survival of patients with pancreatic adenocarcinoma receiving gemcitabine, according to an analysis of clinical data and cancer tissue collected from the European Study Group for ...

Leukemia

In CLL With Coexisting Conditions, Chlorambucil Produces Better Outcomes With Obinutuzumab Than With Rituximab

Charlotte Bath  / February 15, 2014

A randomized phase III trial conducted in 26 countries found that combining chlorambucil (Leukeran) with an anti-CD20 antibody—either obinutuzumab (Gazya) or rituximab (Rituxan)—produced better outcomes among patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting condit...

Multiple Myeloma

Pomalidomide Plus Low-Dose Dexamethasone: Important New Option in Relapsed/Refractory Multiple Myeloma

Charlotte Bath  / February 15, 2014

Pomalidomide (Pomalyst) plus low-dose dexamethasone significantly improved progression-free survival compared to pomalidomide alone in patients with relapsed and refractory multiple myeloma enrolled in a multicenter, open-label study, the phase II part of the MM-002 trial. The study confirmed the sy...

Issues in Oncology

Anticipated Shortage of Oncologists Will Strain Ability to Provide Quality Cancer Care

Charlotte Bath  / February 15, 2014

An update of the ASCO 2007 oncology workforce study found that the Patient Protection and Affordable Care Act, when fully implemented, may “modestly exacerbate” anticipated workforce shortages, increasing the demand for oncologists and radiation oncologists by 500,000 visits per year. “Unless oncolo...

Leukemia

Role for Reduced-Intensity Conditioning Regimen in AML After Allogeneic Transplantation

Charlotte Bath  / February 15, 2014

Reduced-intensity conditioning and myeloablative-conditioning regimens following allogeneic hematopoietic cell transplantation in children with acute myeloid leukemia (AML) resulted in comparable survival, according to a study published in Blood. The study evaluated 181 patients, 39 treated with red...

Breast Cancer

Final Overall Survival Data Show Better Results With Higher Dose of Fulvestrant

Charlotte Bath  / February 1, 2014

Among patients with locally advanced or metastatic estrogen receptor–positive breast cancer, fulvestrant (Faslodex) given at 500 mg “is associated with a 19% reduction in risk of death and a 4.1-month difference in median overall survival compared with fulvestrant 250 mg,” according to final results...

Lung Cancer

Some Lung Cancers Detected by Low-Dose CT in National Lung Screening Trial May Be Indolent

Charlotte Bath  / February 1, 2014

More than 18% of all lung cancers detected by low-dose computed tomography in the National Lung Screening Trial (NLST) may be clinically insignificant. Overdiagnosis should be considered when describing the risks of [low-dose computed tomography] screening for lung cancer, according to a review of e...

Leukemia

Bosutinib Shows 'Acceptable Safety' in Philadelphia Chromosome–Positive Leukemia

Charlotte Bath  / February 1, 2014

Bosutinib (Bosulif) demonstrated “acceptable safety with manageable toxicities” in a phase I/II study among patients with chronic-phase chronic myeloid leukemia (CML) or advanced Philadelphia chromosome–positive leukemia (accelerated-phase/blast-phase CML or acute lymphoblastic leukemia). Patients h...

Breast Cancer
Supportive Care

No Significant Improvement With Decongestive Therapy vs More Conservative Approach to Treating Arm Lymphedema 

Charlotte Bath  / January 15, 2014

Daily manual lymphatic drainage and bandaging followed by compression garments did not result in significant improvement in lymphedema compared to a more conservative approach with compression garments only, according to a study evaluating 95 women previously treated for breast cancer with lymphedem...

Breast Cancer
Gynecologic Cancers

Effects of Oral Contraceptives on Breast/Ovarian Cancer Risks Are Similar Regardless of BRCA Mutation Status

Charlotte Bath  / January 15, 2014

The effects of oral contraceptives on breast and ovarian risks are similar for women with BRCA1 or BRCA2 mutations and for women in the general population, according to analyses of observational studies. Oral contraceptive use “is inversely associated with ovarian cancer risk, whereas a modest but n...

Lymphoma

Increased Ultraviolet Radiation Exposure May Protect Against HL, Particularly in Those With EBV-Positive Disease

Charlotte Bath  / January 15, 2014

Increased exposure to ultraviolet radiation may offer protection against Hodgkin lymphoma (HL), particularly against Epstein-Barr virus (EBV)-positive HL, according to a pooled analysis of studies involving 1,320 HL patients and 6.381 controls.  “Our pooled analysis of 7,701 participants from 4 ind...

Issues in Oncology

African Americans Report Receiving Few Positive Recommendations by Physicians About Joining Clinical Trial 

Charlotte Bath  / January 15, 2014

A study among African American patients with cancer who had declined to participate in a therapeutic clinical trial found that few patients reported receiving a positive recommendation from their physician to participate in the trial. “Patients gave multiple refusal reasons,” researchers led by Rich...

Gastrointestinal Cancer

Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy

Charlotte Bath  / December 15, 2013

Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials co...

Multiple Myeloma

Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Myeloma

Charlotte Bath  / December 15, 2013

A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%,” and when minor responses were included, 75.9%,” researchers reported in Blood. “The s...

Geriatric Oncology

Using Life Expectancy, Not Age, to Make Cancer Screening Decisions Can Maximize Potential Benefits

Charlotte Bath  / December 15, 2013

Using life expectancy, rather than chronologic age, to inform decisions about whether to continue cancer screening for older persons can maximize the potential benefits of screening, while minimizing the harms, according to results of a population-based cohort study of 407,749 people over 66 without...

Issues in Oncology
Survivorship

Oncologists Need to Inform Primary Care Physicians About Late and Long-Term Effects of Chemotherapy

Charlotte Bath  / December 15, 2013

A nationally representative survey of 1,130 oncologists and 1,072 primary care physicians found that primary care physicians had limited awareness of late or long-term effects of chemotherapy agents. This was attributed to primary care physicians not typically encountering chemotherapy agents and/or...

Issues in Oncology

Promoting Timely Referral to Reproductive Specialists for Patients Concerned About Fertility 

Charlotte Bath  / December 15, 2013

Updated clinical guidelines published this year by ASCO “give oncology care providers an opportunity to partner with their reproductive specialist colleagues to ensure that the clinical and psychosocial needs of patients with cancer are addressed as close to the time of diagnosis as possible,” accor...

Issues in Oncology

Young Tobacco Consumers Frequently Use Products Other Than Cigarettes

Charlotte Bath  / December 15, 2013

“A substantial proportion of youth tobacco use occurs with products other than cigarettes, so monitoring and prevention of youth tobacco use needs to incorporate other products, including new and emerging products,” according to the Morbidity and Mortality Weekly Report, published by the Centers for...

Colorectal Cancer

One in Three American Adults Do Not Comply With Screening Guidelines for Colorectal Cancer 

Charlotte Bath  / December 1, 2013

The percentage of American adults aged 50 to 75 who are up-to-date with recommended screening for colorectal cancer “increased from 54% in 2002 to 65% in 2010, primarily driven by increased use of colonoscopy,” according to data from the 2012 Behavioral Risk Factor Surveillance System survey. Howeve...

Breast Cancer

Nodal Status and Tumor Size Predicted Late Recurrences of ER-Positive Breast Cancer in Postmenopausal Women 

Charlotte Bath  / December 1, 2013

Only nodal status and tumor size provided statistically significant prognostic information for predicting recurrences 5 to 10 years after diagnosis for postmenopausal women with early estrogen receptor–positive breast cancer enrolled in the monotherapy arms of the ATAC (Arimidex, Tamoxifen, Alone or...

Gynecologic Cancers

Impact of Pelvic Radiotherapy and Lymphadenectomy on Endometrial Cancer Mortality 

Charlotte Bath  / December 1, 2013

Analysis of data from 58,172 patients identified from Surveillance, Epidemiology, and End Results (SEER) registries as having stage I or II endometrial adenocarcinoma found that pelvic radiotherapy and lymphadenectomy were associated with statistically significantly reduced noncancer mortality, part...

Breast Cancer

Variations in Risk Factors Suggest Distinct Etiology for Inflammatory Breast Cancer

Charlotte Bath  / November 15, 2013

“Varying risk factor associations between inflammatory and noninflammatory breast cancer suggest a distinct etiology for [inflammatory] breast cancer,” according to a study in the Journal of the National Cancer Institute. High body mass index was shown to increase risk of inflammatory breast cancer ...

Breast Cancer

Impact of Hormone Replacement Therapy on Breast Cancer Risk Varies by Race, Weight, and Breast Density

Charlotte Bath  / November 15, 2013

The impact of hormone replacement therapy on breast cancer risk varies according to the patient’s to race/ethnicity, body mass index, and breast density. An analysis of 1,642,824 screening mammograms with 9,300 breast cancer cases in postmenopausal women aged 45 years or older found that hormone rep...

Breast Cancer

Calcium Channel Blockers Linked to Increased Risk of Lobular/Ductal Breast Cancer  

Charlotte Bath  / November 1, 2013

Women who are currently using calcium channel blockers and have been doing so for 10 or more years are at increased risk of the two most common histologic types of breast cancer, invasive ductal carcinoma and invasive lobular carcinoma, according to a population-based case control study. “While som...

Leukemia

Front-Line Treatment Strategies to Achieve Long-Term Control of CLL Combined With Optimal Quality of Life 

Charlotte Bath  / November 1, 2013

“The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes. Several new drugs have been approved for CLL treatment (fludarabine, bendamustine [Treanda], and the monoclonal antibodies alemtuzumab [Campath], rituximab [Rituxan], and ofatumumab [Arzerra]), and many more drugs ...

Palliative Care

Inequality in Delivery of Palliative Radiotherapy Among Black Patients With Cancer and Elderly With Comorbidities  

Charlotte Bath  / November 1, 2013

An analysis of data from more than 51,000 patients with stage IV cancer shows “significant inequality” in the delivery of palliative radiotherapy among the elderly, patients with comorbidity, and black patients with prostate and colorectal cancer, reported James D. Murphy, MD, MS, and colleagues fro...

Breast Cancer

Mindfulness-Based Stress Reduction Therapy for Patients With Distress 

Charlotte Bath  / October 15, 2013

Mindfulness-based cancer recovery was shown to be superior to supportive-expressive group therapy “for decreasing symptoms of stress and also for improving overall quality of life and social support” among women who had stage I to III breast cancer and were assessed as experiencing distress, researc...

Multiple Myeloma

Pomalidomide In Patients With Disease Progression Who Are Refractory to Bortezomib and Lenalidomide  

Charlotte Bath  / October 15, 2013

The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide [Revlimid] and bortezomib [Velcade],” according to a review of clinical data leading to the drug’s approval by the FDA. In February, ...

Skin Cancer

Sunscreen Use Infrequently Discussed With Patients  

Charlotte Bath  / October 15, 2013

Although the incidence of skin cancer in increasing, “the rate at which physicians are mentioning sunscreen at patient visits is quite low, even for patients with a history of skin cancer,” according to an analysis of data from more than 18.30 billion patient visits. “Sun-protection counseling ranks...

Prostate Cancer

Shiftworkers Likely to Have Increased Risk  

Charlotte Bath  / October 15, 2013

A strong positive association with shiftwork and elevated prostate-specific antigen (PSA) level was found in an analysis of three National Health and Nutrition Examination Survey (NHANES) studies. “Our data support the notion that sleep or circadian disruption is associated with elevated PSA, indica...

Pancreatic Cancer

High-Quality Diet May Reduce Risk 

Charlotte Bath  / October 15, 2013

Consuming a high-quality diet, consistent with the Dietary Guidelines for Americans 2005, may reduce the risk of pancreatic cancer, a dietary pattern analysis study found. “This finding contrasts with previous studies showing limited associations with specific foods or nutrients,” the authors report...

Skin Cancer

Low Risk of Transformation to Melanoma for Biopsy-Diagnosed Mildly or Moderately Dysplastic Nevi 

Charlotte Bath  / September 15, 2013

The risk of transformation to melanoma appears very low for biopsy-diagnosed mildly or moderately dysplastic nevi, and routine surgical excision of nevi with a positive biopsy margin may not be indicated. Patients with biopsy-diagnosed moderately-to-severely and severely atypical nevi, however, have...

Skin Cancer

Indoor Tanning Common Among Young White Females Despite Skin Cancer Risk 

Charlotte Bath  / September 15, 2013

Indoor tanning, defined as using a tanning booth, sun bed, or sunlamp, is common among non-Hispanic white female high school students and young adults, despite risks of melanoma and nonmelanoma skin cancer, according to a study published online by JAMA Internal Medicine.  Using data from the 2011 n...

Thyroid Cancer

More Prudent Interpretation of Thyroid Ultrasound Could Reduce Unnecessary Biopsies 

Charlotte Bath  / September 15, 2013

Thyroid ultrasound imaging could be used to identify patients who have a low risk of thyroid cancer for whom biopsy could be deferred, according to a retrospective case-control study reported in JAMA Internal Medicine. Reviewing 11,618 thyroid ultrasound imaging examinations from 8,806 patients iden...

Head and Neck Cancer

Many Patients With Head and Neck Cancer Report Being Depressed, but Few Use Mental Health Services  

Charlotte Bath  / September 15, 2013

Despite a relatively high rate of depression among patients with head and neck cancer following radiation therapy, mental health services were severely underutilized in this group, concluded researchers who analyzed questionnaire results from 211 patients. The patients had been previously treated wi...

Multiple Myeloma

Panobinostat Combined With Bortezomib and Dexamethasone Can Recapture Responses in Heavily Pretreated Patients 

Charlotte Bath  / September 15, 2013

The combination of the investigational histone deacetylase inhibitor panobinostat (Faridak) with bortezomib (Velcade) and dexamethasone was able to recapture responses in 34.5% of heavily pretreated, bortezomib-refractory patients with multiple myeloma in the phase II PANORAMA 2 trial. The 55 patien...

Leukemia

Cord Blood Transplantation Benefits Some Children With Juvenile Myelomonocytic Leukemia 

Charlotte Bath  / September 15, 2013

A retrospective analysis of 110 patients with juvenile myelomonocytic leukemia found that single-unit, unrelated donor umbilical cord blood transplantation resulted in a 5-year disease-free survival rate of 44%. “Our data document that a significant proportion of children with this disease, especial...

Breast Cancer

Nodal Metastases More Likely if Tumors Have Breast Cancer Stem and Progenitor Cells With PI3K/Akt Signaling Defects 

Charlotte Bath  / September 1, 2013

Patients with breast tumors in which breast cancer stem and progenitor cells have a genetic abnormality of the PI3K/Akt signaling pathway are more likely to have lymph node metastases, according to a study in JAMA Surgery. “These oncogenic defects may be missed by gross molecular testing of the tumo...

Breast Cancer

Long-Term Current Use of Calcium Channel Blockers Is Associated With Higher Risk of Breast Cancer  

Charlotte Bath  / September 1, 2013

Long-term use of a calcium channel blocker to treat hypertension is associated with higher breast cancer risk, according to a report published online by JAMA Internal Medicine. Researchers evaluated associations between various classes of hypertensives, the most commonly prescribed class of medicati...

Gynecologic Cancers

'Best-Ever' Published Prognostic Factor for Early-Stage Type 1 Endometrial Cancer 

Charlotte Bath  / September 1, 2013

Immunohistochemical demonstration of the L1 cell adhesion molecule (L1CAM; CD171) “has been shown to be the best-ever published prognostic factor” in Federation Internationale de Gynecologie et d’Obstetrique (FIGO) stage I, type I endometrial cancers “and shows clear superiority over the standardly ...

Prostate Cancer

Printed and Web-Based Decision Aids Improved Informed Decision-Making but Didn’t Alter Screening 

Charlotte Bath  / September 1, 2013

Amid conflicting recommendations for prostate cancer screening and mixed messages communicated to the public about screening effectiveness, decision aids can assist men in making informed choices. A comparison of two different types of decision aids, one print-based and one Web-based, found that bot...

Breast Cancer

Women with Primary Breast Cancer Diagnosed During Pregnancy Have Overall Survival Similar to Nonpregnant Patients 

Charlotte Bath  / August 15, 2013

Results from an international collaborative study showed that women with primary breast cancer diagnosed during pregnancy had overall survival similar to nonpregnant patients. Reporting their findings in the Journal of Clinical Oncology, the authors concluded: “This information is important when pat...

Breast Cancer

Cisplatin plus Cetuximab vs Cisplatin Alone in Patients with Metastatic Triple-negative Breast Cancer

Charlotte Bath  / August 15, 2013

Adding cetuximab (Erbitux) to cisplatin doubled the overall response rate and appeared to prolong progression-free and overall survival in a randomized phase II study among patients with metastatic triple-negative breast cancer. Although the trial did not meet its primary endpoint of overall respons...

Breast Cancer

For Women ≥ 70 Years with Early Breast Cancer, Adding Radiotherapy to Lumpectomy and Tamoxifen Does Not Increase Survival 

Charlotte Bath  / August 15, 2013

Long-term follow-up of Cancer and Leukemia Group B (CALGB) trial 9343 confirmed and extended 5-year results that in women age ≥ 70 years with clinical stage I, estrogen receptor (ER)-positive breast cancer treated with lumpectomy followed by tamoxifen, “irradiation adds no significant benefit in ter...

Prostate Cancer

Androgen Deprivation Therapy Associated with Increased Risk of Acute Kidney Injury  

Charlotte Bath  / August 15, 2013

The use of androgen deprivation therapy was significantly associated with an increased risk of acute kidney injury among men with newly diagnosed nonmetastatic prostate cancer, according to a study published in JAMA. The study was motivated by the increasing use of androgen deprivation therapy in pa...

Skin Cancer

Anti-PD-1 Antibody Lambrolizumab Produces Durable Responses with Low Toxicity in Patients with Advanced Melanoma  

Charlotte Bath  / August 15, 2013

Lambrolizumab produced a high rate of sustained tumor regression when tested among 135 patients with advanced melanoma in a multi-institutional, international, phase I expansion study reported in The New England Journal of Medicine. At a median follow-up of 11 months, responses were durable in the m...

Sarcoma

Ridaforolimus Delayed Tumor Progression in Patients with Previously Treated Metastatic Sarcoma  

Charlotte Bath  / August 15, 2013

“Ridaforolimus delayed tumor progression to a small statistically significant degree in patients with metastatic sarcoma who experienced benefit with prior chemotherapy,” according to results of an international phase III trial. The large randomized placebo-controlled phase III trial evaluated the m...

Leukemia

ATRA and Arsenic Trioxide May Be Even Better Than ATRA and Chemotherapy in Treating Low-to-Intermediate Risk Acute Promyelocytic Leukemia 

Charlotte Bath  / August 15, 2013

All-trans retinoic acid (ATRA) plus arsenic trioxide bested the already high remission rates achieved by ATRA with chemotherapy, the standard of care for acute promyelocytic leukemia, in a phase III multicenter trial among patients with low-to-intermediate risk acute promyelocytic leukemia. “Complet...

Lung Cancer

Most Patients Receiving Radiotherapy for Incurable Lung Cancer Do Not Realize It Is Unlikely to Cure Them 

Charlotte Bath  / July 25, 2013

Surveying a population-based and health system–based cohort of patients receiving radiation therapy for incurable lung cancer (defined as stage IV or stage IIIB with malignant effusion at diagnosis) revealed that “64% did not understand that [radiotherapy] was not at all likely to cure them.” These ...

Prostate Cancer

Use of Advanced Technologies Has Increased in Men at Low Risk of Dying from Prostate Cancer 

Charlotte Bath  / July 25, 2013

The use of advanced treatment technologies, such as intensity-modulated radiotherapy and robotic prostatectomy, has increased among men unlikely to die from prostate cancer, according to a retrospective analysis of data from almost 56,000 men diagnosed with prostate cancer between 2004 and 2009. Amo...

Prostate Cancer

Pain Is More Prevalent and Severe in Men with Metastatic Disease and Use of Docetaxel  

Charlotte Bath  / July 25, 2013

Men who have metastatic castration-resistant prostate cancer and have used docetaxel reported a higher prevalence and greater severity of pain than docetaxel-naive patients, according to results of an anonymous survey conducted at five comprehensive cancer centers in the Prostate Cancer Clinical Tri...

Breast Cancer

Two Studies Indicate Potential Predictors of Survival Benefit from Endocrine Therapy 

Charlotte Bath  / July 25, 2013

Two studies published in Journal of Clinical Oncology indicate that treatment-related symptoms and mammographic density reduction may predict whether a woman with hormone receptor–positive breast cancer will benefit from adjuvant endocrine therapy. In one study, women who had specific adverse events...

Leukemia
Geriatric Oncology

Lenalidomide Induces Long-lasting Responses in Elderly Patients

Charlotte Bath  / July 25, 2013

Treatment with lenalidomide (Revlimid) as initial therapy induced long-lasting responses in a phase II study of 60 patients with chronic lymphocytic leukemia (CLL). “Overall, 35 patients (58%) patients had responses lasting more than 36 months and were considered long-term responders,” the researche...

Some Excess Cancer Risk in Men May Be Related to Greater Height  

Charlotte Bath  / July 25, 2013

More than one-third of the excess risk for cancers among men may be due to factors associated with height, according to data from the Vitamins and Lifestyle (VITAL) study. As reported in the Journal of the National Cancer Institute, these factors include the “number of susceptible cells in a specifi...

Breast Cancer

Survival Benefits of DCIS Management Strategies Compared 

Charlotte Bath  / July 10, 2013

Overall survival benefits of six management strategies for ductal carcinoma in situ (DCIS) are within 1 year of each other, according to a disease simulation model integrating empirical data from published literature and quantifying the tradeoffs among the different management strategies with respec...

Breast Cancer

Cognitive Complaints after Breast Cancer Treatment and Neuropsychological Testing

Charlotte Bath  / July 10, 2013

About one in five patients who had completed primary breast cancer treatments but had not started endocrine therapy “had elevated memory and/or executive function complaints that were statistically significantly associated with domain-specific” neuropsychological test performances and depressive sym...

Kidney Cancer

Using Quality Indicators Can Improve Outcomes among Patients with Renal Cell Carcinoma

Charlotte Bath  / July 10, 2013

An expert panel of 13 urologic and medical oncologists worked together to identify 23 quality indicators for renal cell carcinoma, as described in an article in the Journal of Oncology Practice. “These 23 [quality indicators] will provide a means of evaluating the quality of [renal cell carcinoma] c...

Prostate Cancer

Replacing Animal Fat with Vegetable Fat May Reduce Mortality Risk in Men with Nonmetastatic Disease

Charlotte Bath  / July 10, 2013

“Among men with nonmetastatic prostate cancer, replacing carbohydrates and animal fat with vegetable fat may reduce the risk of all-cause mortality,” according to a prospective study of 4,577 men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study. Vegetable fat intake aft...

Lymphoma

Plasma Epstein-Barr Virus DNA a Potential Marker for Treatment Response in Advanced Hodgkin Lymphoma 

Charlotte Bath  / July 10, 2013

Plasma Epstein-Barr Virus (EBV) DNA has prognostic significance in Hodgkin lymphoma, both prior to therapy and at 6 months of follow-up, according to results of a study published in Blood. “Plasma EBV-DNA positivity at month 6 is associated with particularly poor outcomes and may serve as an indicat...

Colorectal Cancer

Liver-first Approach to Colorectal Cancer with Synchronous Hepatic Metastases

Charlotte Bath  / June 25, 2013

“The liver-first approach for patients with colorectal cancer with synchronous liver metastases is possible but is associated with a wide range of survival outcomes, despite protocol similarities between studies,” according to a review of four cohort studies identified by a literature search. “All ...

Breast Cancer
Issues in Oncology

Chemotherapy-induced Peripheral Neuropathy Results in Dose Limiting and Less Chemotherapy Overall

Charlotte Bath  / June 25, 2013

Chemotherapy-induced peripheral neuropathy events resulted in limiting the dosing of chemotherapy in a significant proportion of women with nonmetastatic breast cancer being treated with paclitaxel, and those who had their dose reduced or discontinued received significantly less cumulative drug, acc...

Breast Cancer

No Added Benefit from Radiotherapy after Lumpectomy/Tamoxifen in Older Women 

Charlotte Bath  / June 25, 2013

Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9343 “confirms and extends the earlier report that in women age ≥ 70 years with clinical stage I, [estrogen receptor (ER)]-positive breast cancer treated with lumpectomy followed by tamoxifen, irradiation adds no significant benefit in terms...

Breast Cancer

DCIS Score Quantifies Risk of Recurrence after Excision

Charlotte Bath  / June 25, 2013

The ductal carcinoma in situ (DCIS) Score, a multigene expression assay, quantifies the risk of local recurrence and invasive local recurrence for women with DCIS treated with surgical excision, researchers reported in the Journal of the National Cancer Institute. “The DCIS Score can aid clinical de...

Breast Cancer
Issues in Oncology

Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy 

Charlotte Bath  / June 10, 2013

Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need chemotherapy,” investigators ...

Breast Cancer

Surgery Delays Longer Than 6 Weeks in Young Women with Breast Cancer Decrease Survival 

Charlotte Bath  / June 10, 2013

Delays of more than 6 weeks from time of diagnosis until surgical treatment of breast cancer among young women significantly decreases survival times compared to those with a shorter treatment delay time, according to a study in JAMA Surgery. “This adverse impact on survival was more pronounced in A...

Breast Cancer

Black, Asian, and Younger Women at Increased Risk of PTSD after Diagnosis of Localized Breast Cancer 

Charlotte Bath  / June 10, 2013

Nearly one-quarter of women in a large prospective study of racially diverse patients with stage I to III breast cancer reported symptoms consistent with posttraumatic stress disorder (PTSD), with increased risk of PTSD among black, Asian, and younger women. “These potential risk factors can be iden...

Breast Cancer
Issues in Oncology

Smoking Early in Life Is More Strongly Associated with Increased Risk of Breast Cancer 

Charlotte Bath  / June 10, 2013

Analyses of data from 73,388 women in the American Cancer Society’s Cancer Prevention Study II (CPS-II) Nutrition Cohort and from a meta-analysis including 14 other studies “support the hypothesis that active smoking increases the risk of breast cancer, especially when smoking begins at an early age...

Supportive Care
Palliative Care

Older Patients and Those with Comorbidities Are Less Likely to Receive Palliative Radiotherapy 

Charlotte Bath  / June 10, 2013

Older patients and those with comorbid conditions are less likely to receive palliative radiotherapy, according to an analysis of data from 51,610 patients with stage IV breast, prostate, lung, or colorectal cancer. The study also found that black patients with prostate cancer were 20% less likely t...

Supportive Care

Patients with Cancer Can Have Cachexia-related Poor Prognostic Factors Regardless of Overall Weight 

Charlotte Bath  / June 10, 2013

“Patients with cancer who are cachexic by the conventional criterion (involuntary weight loss) and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight,” concluded a study in the Journal of Clinical Oncology. Researchers ...

Breast Cancer

Exemestane an Adjuvant Option for Postmenopausal Hormone Receptor–positive Breast Cancer

Charlotte Bath  / May 15, 2013

A phase III open-label trial of exemestane vs anastrozole in postmenopausal women with hormone-dependent early breast cancer found that both agents produced similar median rates of event-free survival—91% for exemestane and 91.2% for anastrozole—as well as similar distant disease-free and disease-sp...

Gynecologic Cancers

Higher Prediagnosis Body Mass Index Raises Mortality Risk in Endometrial Cancer

Charlotte Bath  / May 15, 2013

Higher prediagnosis body mass index (BMI) increases risk of overall and disease-specific mortality among women diagnosed with endometrial cancer, suggested a study published in the Journal of the National Cancer Institute. Physical activity was associated with reduced risk of all-cause, but not dise...

Leukemia

High-dose Liposomal Vincristine Produces Durable Responses in Advanced ALL

Charlotte Bath  / May 15, 2013

High-dose monotherapy with vincristine sulfate liposome injection (Marqibo) resulted in meaningful clinical outcomes, including durable responses and bridging to hematopoietic cell transplantation, in adult patients with advanced, relapsed, and refractory Philadelphia chromosome (Ph)-negative acute ...

Kidney Cancer

Cisplatin and Radiotherapy Linked to Increased Renal Cancer Risk in Childhood Cancer Survivors

Charlotte Bath  / May 15, 2013

Survivors of childhood cancer have an increased risk of subsequent renal cancers compared to the general population, researchers reported in the Journal of the National Cancer Institute. The risk is particularly high among survivors of neuroblastoma and those who have had irradiation involving the k...

Issues in Oncology

Ruxolitinib Results in Clinically Meaningful Symptom Improvement 

Charlotte Bath  / May 15, 2013

Patients with myelofibrosis who received ruxolitinib (Jakafi) therapy experienced “meaningful reductions in symptom burden” and improvements in quality of life in a double-blind, placebo-controlled phase III trial published in the Journal of Clinical Oncology. The COMFORT-I (Controlled Myelofibros...

High Levels of Psychological Distress Are Common among Parents of Children with Advanced Cancer 

Charlotte Bath  / May 15, 2013

High to severe levels of psychological distress are common among parents of children with advanced cancer, according to a study conducted at three children’s hospitals—Boston Children’s Hospital, Children’s Hospital of Philadelphia, and Seattle Children’s Hospital. The cohort study was embedded in a...

Breast Cancer

Progression-free Survival in HER2-positive Metastatic Breast Cancer Improved with T-DM1 

Charlotte Bath  / May 1, 2013

First-line treatment with ado-trastuzumab emtansine (T-DM1) “provided a significant improvement” in progression-free survival when compared to trastuzumab (Herceptin) plus docetaxel in a randomized phase II study among patients with HER2-positive metastatic or recurrent locally advanced breast cance...

Leukemia

Bortezomib Added to Standard Induction Therapy Produced Encouraging AML Remission Rate  

Charlotte Bath  / May 1, 2013

Adding bortezomib (Velcade) to standard daunorubicin and cytarabine induction chemotherapy for acute myeloid leukemia (AML) “resulted in an encouraging remission rate” in previously untreated older adults, according to results of Cancer and Leukemia Group B (CALGB/Alliance) study 10502. The frequenc...

Leukemia

Successful Salvage Treatment Possible in Some Patients Who Do Not Have a Transplant in First Remission 

Charlotte Bath  / May 1, 2013

Among 3,919 patients with acute myeloid leukemia (AML) who did not undergo transplantation in first complete remission, 1,271 relapsed and 19% were successfully treated with salvage therapy, according to an analysis of three AML trials in the United Kingdom. This percentage can be improved with a tr...

Pain Management

Duloxetine Reduced Painful Chemotherapy-induced Peripheral Neuropathy  

Charlotte Bath  / May 1, 2013

The use of duloxetine (Cymbalta) for 5 weeks “was associated with a statistically and clinically significant improvement” in painful chemotherapy-induced peripheral neuropathy when compared with placebo in a phase III randomized, double-blind crossover trial reported in the Journal of the American M...

Head and Neck Cancer

Two Studies Focus on Treatment Strategies for Preserving the Larynx While Increasing Survival

Charlotte Bath  / April 15, 2013

Two recent studies in the Journal of Clinical Oncology focused on treatment strategies to preserve the larynx while increasing survival of patients with cancer of larynx. RTOG 91-11 Ten-year results from the Radiation Therapy Oncology Group (RTOG) 91-11 trial found that both chemotherapy regimens ...

Lung Cancer

Modified and Updated Risk-prediction Model Is More Efficient in Identifying Persons for Lung Cancer Screening

Charlotte Bath  / April 15, 2013

An updated and modified lung-cancer risk-prediction model developed from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial “was more sensitive” for lung cancer detection than criteria from the National Lung Cancer Screening Trial (NLST), according to a study in TheNew England...

Multiple Myeloma

Thalidomide/Prednisone Maintenance after Stem Cell Transplant Improves Progression-free but Not Overall Survival

Charlotte Bath  / April 15, 2013

Maintenance therapy with thalidomide (Thalomid) and prednisone after autologous stem cell transplantation in patients with multiple myeloma improved progression-free survival but not overall survival, according to results of a phase III trial reported in Blood. Patients receiving maintenance therapy...

Skin Cancer

Trametinib Shows Activity in Previously Treated but BRAF Inhibitor–naive BRAF-mutant Melanoma

The ASCO Post  / March 15, 2013

In a multicenter phase II study, trametinib showed “significant clinical activity” in a cohort of BRAF inhibitor–naive patients with BRAF-mutant cutaneous melanoma previously treated with chemotherapy and/or immunotherapy. Only minimal clinical activity, however, was observed among a cohort of patie...

Gynecologic Cancers

Short-term Survival Advantage of Carrying BRCA Mutation Does Not Extend to Long Term

The ASCO Post  / March 15, 2013

While carrying a BRCA 1 or BRCA 2 mutation was associated with a better prognosis in the 3-year period after diagnosis of invasive ovarian cancer, this short-term survival advantage did not lead to long-term survival benefit, according to a study published in the Journal of the National Cancer Insti...

Leukemia
Lymphoma

Older Patients Do Better with Hematopoietic Transplants from Siblings of Similar Age than from Younger but Unrelated Donors 

The ASCO Post  / March 15, 2013

Patients ≥ 50 years old with leukemia/lymphoma are increasingly undergoing allogeneic hematopoietic cell transplants, raising questions about whether they might have better outcomes with transplants from younger allele-level 8/8 human leukocyte antigen (HLA)-matched unrelated donors than from HLA-ma...

Hematologic Malignancies
Leukemia

Short Wait for Lab Results Is Reasonable Strategy to Better Characterize AML and Design Therapy

The ASCO Post  / March 15, 2013

Waiting a short period of time for laboratory results to better characterize acute myeloid leukemia (AML) and design therapeutic approaches is a reasonable strategy, researchers in Toulouse, France, found after a retrospective review of 599 newly diagnosed AML patients treated by induction chemother...

Kidney Cancer

PET/CT With 124I-Girentuximab Can Identify Clear Cell Renal Cell Carcinoma While Minimizing Invasive Diagnostic Risks 

The ASCO Post  / March 15, 2013

Positron-emission tomography/computed tomography (PET/CT) with iodine-124 (124I) –girentuximab “can accurately and noninvasively identify” clear cell renal cell carcinoma, according to a phase III multicenter study reported in the Journal of Clinical Oncology. In addition, “PET/CT with 124I-girentux...

Issues in Oncology

Large Epidemiologic Studies Re-examine Hazards of Smoking

The ASCO Post  / March 15, 2013

“Smokers lose at least one decade of life expectancy, as compared with those who have never smoked,” and the increased risk of death from cigarettes smoking “are now nearly identical for men and women,” according to two separate studies published online by TheNew England Journal of Medicine. One st...

Colorectal Cancer

Even at NCCN Institutions, a 'Sizable Minority' of Patients with Rectal Cancer Are Not Treated per NCCN Guidelines 

Charlotte Bath  / February 15, 2013

Even at the eight cancer centers participating in the National Comprehensive Cancer Network (NCCN) Colorectal Cancer Outcomes project, a “sizable minority” of patients with stage II/III rectal cancer treated with curative intent neoadjuvant chemoradiotherapy did not complete postoperative chemothera...

CNS Cancers

Surgery of Primary Tumor Site Has No Impact on Local Control and Outcome in Patients ≥ 18 Months with Stage IV Disease 

Charlotte Bath  / February 15, 2013

“In intensively treated patients with stage IV neuroblastoma age 18 months or older at diagnosis, surgery of the primary tumor site has no impact on local control rate and outcome,” according to findings from the German prospective clinical trial NB97. “The results of the study,” the researchers con...

Issues in Oncology

Failure to Screen Patients for Hepatitis B Virus Could Result in Fatal Complications 

Charlotte Bath  / February 15, 2013

Although hepatitis B virus (HBV) reactivation is a potentially fatal complication of chemotherapy, “provided that HBV carriers are recognized, HBV reactivation can be largely prevented through the administration of oral antinucleoside analogs,” researchers at the University of Toronto noted in an ar...

Skin Cancer

Tremelimumab Not Better Than Standard-of-care Chemotherapy in Patients with Advanced Melanoma 

Charlotte Bath  / February 15, 2013

Tremelimumab did not produce a statistically significant advantage in overall survival compared to first-line standard-of-care chemotherapy in a phase III randomized trial reported in the Journal of Clinical Oncology. At final analysis, median overall survival by intent to treat was 12.6 months (95%...

Breast Cancer

Younger Patients with Family History of Breast Cancer at Similar Risk of Bilateral Disease as Those with BRCA Mutations 

Charlotte Bath  / February 1, 2013

Women who are diagnosed with breast cancer before age 55 and have a first-degree family history of bilateral disease have risks of contralateral breast cancer similar to women with deleterious mutations of BRCA1 and BRCA2, according to a study recently published in the Journal of Clinical Oncology, ...

Breast Cancer

Adding Temsirolimus to Letrozole Did Not Improve Survival but Might Benefit Patients under 65

Charlotte Bath  / February 1, 2013

Adding temsirolimus (Torisel) to letrozole did not improve progression-free survival in patients with aromatase inhibitor–naive, estrogen receptor (ER)-positive advanced breast cancer, but exploratory analysis indicated the combination could benefit postmenopausal patients ≤ 65. In their Journal of ...

Prostate Cancer

No Difference in Toxicity with Proton Radiotherapy vs Less Costly Intensity-modulated Radiotherapy 

Charlotte Bath  / February 1, 2013

A national sample of Medicare beneficiaries treated for prostate cancer with intensity-modulated radiation therapy or proton radiotherapy found that proton radiotherapy “was rare and expensive and associated with only a modest and transient reduction in genitourinary toxicity,” reported James B. Yu,...

Lung Cancer
Issues in Oncology

E-mail Reminders to Providers May Improve Documentation of Code Status in Patients with Advanced Disease 

Charlotte Bath  / February 1, 2013

E-mail reminders to providers at the start of each new chemotherapy regimen may improve the rate and timing of code status documentation for patients with advanced lung cancer, according to a study in the Journal of Clinical Oncology. Jennifer S. Temel, MD, and colleagues from Massachusetts General ...

Gynecologic Cancers

Screening and Risk-reduction without Testing Positive for BRCA Mutation

Charlotte Bath  / January 15, 2013

Many women who do not test positive for a BRCA mutation undergo additional ovarian cancer screenings and risk-reducing procedures, despite limited data to determine the effectiveness of these interventions among an average-risk population. Results of an analysis of data from 1,077 women who were sur...

Breast Cancer

Analysis Suggests Screening Mammography Results in Substantial Overdiagnosis with Small Effect on Mortality

Charlotte Bath  / January 15, 2013

An analysis of Surveillance, Epidemiology, and End Results (SEER) data from 1976 through 2008 “suggests that whatever the mortality benefit, breast-cancer screening involved a substantial harm of excess detection of additional early-stage cancers that was not matched by a reduction in late-stage can...

Lung Cancer

Volume-doubling Time May Help Distinguish Aggressive Cancer from Slow-growing Tumors

Charlotte Bath  / January 15, 2013

Changes in the size of lung tumors over time, as measured by volume-doubling times on low-dose computed tomography, can be used to distinguish aggressive lung cancer from slow-growing or indolent tumors and reduce overdiagnosis that could result in overtreatment and unnecessary morbidity. Results fr...

Leukemia

Chlorambucil, but Not Fludarabine, Confers Significant Benefit in Older Patients with CLL

Charlotte Bath  / January 15, 2013

Among patients aged 70 years and older with chronic lymphocytic leukemia (CLL), “front-line therapy with fludarabine does not improve outcomes” compared to chlorambucil (Leukeran), according to an analysis of patients enrolled in successive front-line Cancer and Leukemia Group B (CALGB) studies 9011...

Head and Neck Cancer

Four-plus Cups of Coffee Daily Linked to Lower Risk of Death from Oral/Pharyngeal Cancer 

Charlotte Bath  / January 15, 2013

Consuming four or more cups per day of caffeinated coffee could almost halve the risk of dying from oral/pharyngeal cancer compared to drinking no coffee or drinking it only occasionally, researchers reported in the American Journal of Epidemiology. “A dose-related decline in relative risk was obser...

Multiple Myeloma

Persistent Survival Benefit in Patients with Untreated Disease Treated with Bortezomib Added to Melphalan and Prednisone

Charlotte Bath  / January 15, 2013

A final analysis of the phase III VISTA trial (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone) found a persistent significant benefit in overall survival with VMP (bortezomib, melphalan, prednisone) vs MP (melphalan, prednisone) in patients with mul...

CNS Cancers

Early Surgical Treatment of Low-grade Glioma Improves Survival vs Watchful Waiting

Charlotte Bath  / December 15, 2012

In a comparison of surgical treatment strategies for low-grade gliomas, patients in Norway treated at a hospital that generally favored early surgical resection had better overall survival than patients treated at a hospital that favored diagnostic biopsy and watchful waiting, according to a study p...

Breast Cancer

Small Increase in Cardiac Events for Trastuzumab plus Anthracycline in HER2-positive Disease

Charlotte Bath  / December 15, 2012

A 7-year follow-up of the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-31 found that the cumulative difference in the rate of cardiac events was 3.1% between patients with HER2-positive, node-positive breast cancer who received trastuzumab (Herceptin) in addition ...

Sarcoma

Interval-compressed Chemotherapy More Effective with No Increase in Toxicity

Charlotte Bath  / December 15, 2012

A randomized controlled trial among patients with newly diagnosed localized Ewing sarcoma found that “chemotherapy administered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity,” investigators from the Children’s Oncology Group reported in th...

Hepatobiliary Cancer

Lower Risk of Recurrence in Patients with HBV-related Liver Cancer Receiving Nucleoside Analogs

Charlotte Bath  / December 15, 2012

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma who received nucleoside analogs after curative liver resection had an associated lower risk of hepatocellular carcinoma in a nationwide cohort study using data from the Taiwan National Health Research Data Base. The study was rep...

Risk Reduction for Patients with Multiple Primary Cancers

Charlotte Bath  / November 15, 2012

The number of patients with multiple primary cancers is increasing so that second malignant neoplasms now represent approximately 16%, or 1 in 6 cancers reported to the Surveillance, Epidemiology, and End Results (SEER) Program. While some second malignant neoplasms are treatment-related, others are...

Lymphoma

Novel Mechlorethamine Gel Considered Safe and Effective for Treatment of Mycosis Fungoides

Charlotte Bath  / November 15, 2012

A novel mechlorethamine, 0.02%, gel produced comparable or higher response rates (depending on the measurement used) than did mechlorethamine, 0.02%, compounded ointment, in a randomized controlled, multicenter study among 260 patients with stage IA to IIA mycosis fungoides, the most common form of ...

Issues in Oncology

Media Campaign with Real Smokers a Success

Charlotte Bath  / November 15, 2012

Real smokers sharing in graphic terms what it is like to live with disfiguring or disabling tobacco-related diseases were the featured spokespersons for the Centers for Disease Control and Prevention (CDC) national media campaign to encourage smokers to quit. Based on short-term response, the CDC ha...

Kidney Cancer

Pulmonary Radiotherapy Can Usually Be Omitted for Nephroblastoma and Pulmonary Metastases

Charlotte Bath  / November 15, 2012

For the majority of patients with nephroblastoma and pulmonary metastases, pulmonary radiotherapy can be omitted and the patients will still have a relatively good outcome, according to a study published in the Journal of Clinical Oncology. “The rationale of omitting pulmonary [radiotherapy] for the...

Breast Cancer

Pathologic Nodal Status and Tumor Response Can Predict Risk of Locoregional Recurrence

Charlotte Bath  / November 1, 2012

Pathologic nodal status/breast tumor response following neoadjuvant chemotherapy can be used to predict locoregional recurrence in women with operable, palpable breast cancer (T1-3, N0-1, M0) previously treated with mastectomy or lumpectomy plus radiotherapy. These results from the combined analysis...

Breast Cancer

Short Interval between Initial and Contralateral Breast Cancer Increases Risk of Dying

Charlotte Bath  / November 1, 2012

Breast cancer survivors who develop contralateral breast cancer have an increased risk of dying from breast cancer throughout a follow-up period of 10 or more years, according to a study of a cohort of 42,670 women diagnosed with breast cancer in Sweden. “The added risk is considerable if the [contr...

Colorectal Cancer

Patients with Lynch Syndrome Who Have Had Colorectal Cancer Are at Increased Risk of Other Cancers

Charlotte Bath  / November 1, 2012

Patients who have had colorectal cancer and who are carriers of the DNA mismatch repair gene mutations that cause Lynch syndrome “have an increased risk of a greater range of cancers than the recognized spectrum of Lynch syndrome cancers, including breast and prostate cancers,” according to a study ...

Breast Cancer

Anthracycline/Trastuzumab Treatment Linked to Increased Risk of Heart Failure, Cardiomyopathy

Charlotte Bath  / October 15, 2012

A population-based, retrospective cohort study of 12,500 women diagnosed with incident, invasive breast cancer found that anthracycline and trastuzumab (Herceptin) were associated with increased risk of heart failure and/or cardiomyopathy. “Compared with women who received no chemotherapy, our hazar...

Reduced Disease Progression in Patients with Continued Gemcitabine Maintenance or Erlotinib Switch Maintenance

Charlotte Bath  / October 15, 2012

A phase III study showed that progression-free survival was significantly prolonged with continuation maintenance with gemcitabine or switch maintenance with erlotinib (Tarceva) compared with observation in patients with advanced non–small cell lung cancer (NSCLC) who received first-line treatment w...

Lymphoma
Survivorship

Long-term Survivors of Hodgkin Lymphoma May Have Increased Risk of Neurocognitive Impairment

Charlotte Bath  / October 15, 2012

A “new finding” that long-term survivors of childhood Hodgkin lymphoma may be at risk for neurocognitive impairment and central nervous system (CNS) pathology arose from a study among 62 patients treated with either high-dose (≥ 30 Gy) thoracic radiation or lower-dose (< 30 Gy) thoracic radiation...

Prostate Cancer

Enzalutamide Significantly Prolonged Survival in Men with Castrate-resistant Metastatic Prostate Cancer

Charlotte Bath  / September 15, 2012

“Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy” in an international phase III, double-blind, placebo-controlled trial, investigators reported in The New England Journal of Medicine. Median overall survival, the primar...

Colorectal Cancer

Cetuximab Dose Escalation May Increase Responses among Patients with Mild or No Initial Skin Reactions

Charlotte Bath  / September 15, 2012

Escalating the dose of cetuximab (Erbitux) among patients with metastatic colorectal cancer who developed no or mild skin reactions on standard-dose cetuximab plus irinotecan “seemed to lead to an increase in response rate” as well as in the disease-control rate, according to a phase I/II study repo...

Colorectal Cancer

Patients with Unresectable Metastases Can Be Spared Noncurative Resection of Intact Primary Tumor

Charlotte Bath  / September 15, 2012

Patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor can be spared initial noncurative resection of their intact primary tumor, National Surgical Adjuvant Breast and Bowel Project (NSABP) C-10 trial investigators reported in the Journal of Clinical O...

High-cost Imaging Used Frequently in Elderly with Stage IV Cancer

Charlotte Bath  / September 15, 2012

Patients with stage IV breast, colorectal, lung, and prostate cancers undergo frequent high-cost imaging procedures throughout the continuum of their care, and rates of imaging have steadily increased, according to an analysis of claims from the Surveillance, Epidemiology, and End Results (SEER)-Med...

New Agents That Improve Efficacy Can Also Increase Morbidity and Treatment-related Mortality

Charlotte Bath  / September 1, 2012

Newly approved anticancer drugs that lead to improvements in efficacy can also lead to increased morbidity and treatment-related mortality, according to a study in the Journal of Clinical Oncology. The investigators conducted a meta-analysis of 38 randomized controlled trials evaluating agents appro...

Breast Cancer

Taxane-induced Neuropathy Does Not Correlate with Improved Outcomes in Operable Breast Cancer

Charlotte Bath  / September 1, 2012

An analysis of 4,554 patients who received adjuvant weekly paclitaxel and other taxane-based regimens in the E1199 trial “demonstrated that taxane-induced peripheral neuropathy does not correlate with improved outcomes in patients with operable breast cancer,” investigators reported in the Journal o...

Kidney Transplant Recipients Switching to Sirolimus Had Lower Risk of Secondary Squamous Cell Carcinomas

Charlotte Bath  / September 1, 2012

Kidney transplant recipients with at least one previous cutaneous squamous cell carcinoma decreased their risk of developing new cutaneous squamous cell carcinomas by switching from calcineurin inhibitors (cyclosporine or tacrolimus) to sirolimus (Rapamune) in a multicenter phase III study. New squa...

Lung Cancer

Study Reports ‘Strong and Consistent Relation’ between Exposure to Diesel Exhaust and Risk of Dying of Lung Cancer

Charlotte Bath  / August 15, 2012

A nested case-control study of 198 lung cancer deaths among a cohort of 12,315 mine workers “showed a strong and consistent relation between quantitative exposure to diesel exhaust and increased risk of dying of lung cancer,” researchers reported in the Journal of the National Cancer Institute.1 “To...

Lung Cancer

Response Rate Is Significantly Improved with Nab- vs Solvent-based Paclitaxel plus Carboplatin in Advanced NSCLC

Charlotte Bath  / August 15, 2012

Final results of a phase III trial found nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus carboplatin as first-line therapy in patients with advanced non–small cell lung cancer (NSCLC) resulted in a significantly improved overall response rate vs conventional solvent-based paclitaxel plus...

Lymphoma

Children with Favorable-risk Disease and Complete Response to Chemotherapy Have High Survival Rates without Radiotherapy

Charlotte Bath  / August 15, 2012

Among children with favorable-risk Hodgkin lymphoma, those who achieved a complete response after two cycles of chemotherapy and received no radiotherapy had high rates of survival similar to those who had a less complete response to chemotherapy and received radiotherapy, according to a study in th...

CNS Cancers

Bevacizumab/Temozolomide Combination Safe and Active against Advanced Neuroendocrine Tumors

Charlotte Bath  / August 15, 2012

The combination of bevacizumab (Avastin) and temozolomide can be safely administered together in patients with advanced neuroendocrine tumors, and “the combination regimen appears promising for patients with pancreatic [neuroendocrine tumors],” according to results of a phase II study reported in th...

Solid Tumors

‘Strong Persistent Benefit’ from Radiochemotherapy after Curative Gastric Cancer Resection

Charlotte Bath  / August 15, 2012

An update, with more than a 10-year median follow-up, from Intergroup 0116 (INT-0116), a randomized phase III trial of postoperative chemotherapy in patients at moderate risk of locoregional failure following curative gastric cancer resection, “demonstrates strong persistent benefit from adjuvant ra...

Pancreatic Cancer

Adjuvant Chemotherapy May Improve Survival for Patients with Periampullary Disease

Charlotte Bath  / August 15, 2012

The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary cancer trial found that adjuvant chemotherapy following surgical resection of periampullary adenocarcinoma “was not associated with a significant survival benefit in the primary analysis; however, multivariate analysis adjusting ...

Solid Tumors

Regorafenib Has ‘Notable Anticancer Activity’ after Patients Develop Resistance to Imatinib and Sunitinib

Charlotte Bath  / August 15, 2012

The orally administered investigational multikinase inhibitor regorafenib demonstrated “notable anticancer activity” in a phase II trial among patients with advanced gastrointestinal stromal tumor (GIST) who developed resistance to imatinib (Gleevec) and sunitinib (Sutent). Researchers reported in t...

Gastroesophageal Cancer

Most Hospitals Do Not Meet Benchmark for Examining Lymph Nodes following Esophagectomy

Charlotte Bath  / August 15, 2012

“Fewer than one-third of patients and fewer than 1 in 10 hospitals met the benchmark of examining at least 15 lymph nodes” following esophagectomy for patients with esophageal cancer, according to a retrospective observational study reported in the Archives of Surgery. That benchmark was set by the ...

Solid Tumors

Screening Should Begin Early for Survivors of Childhood Cancer

Charlotte Bath  / July 15, 2012

Survivors of childhood cancer, particularly those treated for childhood Hodgkin lymphoma or Wilms tumor with abdominal radiation, procarbazine (Matulane), and platinum chemotherapy, are at an increased risk of developing gastrointestinal subsequent malignant neoplasms, according to a retrospective c...

Colorectal Cancer

Adjuvant Chemotherapy May Confer Survival Benefit in Patients Older than 75 with Stage III Disease

Charlotte Bath  / July 15, 2012

Because few people over 75 participate in clinical trials, it is unknown whether adjuvant chemotherapy could benefit this population. Faced with this gap in clinical trial evidence, researchers reviewed data from 5,489 patients ≥ 75 years with stage III colon cancer. The review suggests that patient...

Lymphoma

After Complete Response to Chemotherapy, IFRT Improves Event-free Survival in Hodgkin Lymphoma

Charlotte Bath  / July 1, 2012

Final data from the Children’s Cancer Group (CCG) trial evaluating low-dose involved-field radiation therapy (IFRT) for patients with Hodgkin lymphoma achieving a complete response after chemotherapy show that at a median follow-up of 7.7 years, IFRT produced a statistically significant improvement ...

Thyroid Cancer

Obese Patients at Higher Risk of Aggressive Thyroid Tumors

Charlotte Bath  / July 1, 2012

Obese patients present with more advanced and more aggressive forms of papillary thyroid cancer and should be screened for thyroid cancer with sonography, which is more sensitive in detecting thyroid cancer than physical examination alone, according to a study published online in the Archives of Sur...

Pain Management
Palliative Care

Pain Remains Prevalent and Often Inadequately Treated among Cancer Outpatients

Charlotte Bath  / June 15, 2012

“Pain is as prevalent in ambulatory oncology patients with common solid tumors as it was more than 20 years ago, despite the fact that opioid prescribing in the United States has increased more than 10-fold since 1990,” according to results of a study among 3,023 ambulatory patients with cancer iden...

Pain Management

Screening for Distress and Unmet Needs in Patients with Cancer

Charlotte Bath  / June 15, 2012

In the past decade, “screening for distress has been positioned as the sixth vital sign in cancer care, in addition to the first five, which are measurements of pulse, respiration, blood pressure, temperature, and pain,” according to a review article in the Journal of Clinical Oncology. Although dis...

Thyroid Cancer

Low-dose Radioiodine as Effective as High-dose in Thyroid Ablation

Charlotte Bath  / June 15, 2012

Two studies in The New England Journal of Medicine found that low-dose radioiodine is as effective as a high-dose strategy in treating patients with thyroid cancer and that recombinant human thyrotropin (thyrotropin alfa [Thyrogen]) and thyroid hormone withdrawal had similar efficacy in preparing pa...

Lymphoma

Panobinostat Produces Objective Responses in Patients Refractory to Autologous Transplant

Charlotte Bath  / June 15, 2012

Panobinostat produced objective responses in 27% and tumor reductions in 74% of 129 patients enrolled in “the largest, prospective, multicenter, international trial conducted in heavily pretreated patients” with Hodgkin lymphoma who relapsed or were refractory to autologous stem cell transplantation...

Leukemia

Pediatric ALL with Induction Failure Is Highly Heterogeneous with Varying Outcomes

Charlotte Bath  / June 15, 2012

While failure of remission-induction therapy is rare in children and adolescents with acute lymphoblastic leukemia (ALL), when it does occur it is highly adverse and heterogeneous, according to a study in The New England Journal of Medicine. “Patients who have T-cell leukemia appear to have a better...

Gynecologic Cancers

Scoring System Based on DNA Repair Pathways Predicts Outcomes and Response to Platinum Therapy

Charlotte Bath  / June 15, 2012

A potentially important tool to identify patients with advanced-stage ovarian cancer likely to benefit from platinum-based chemotherapy and redirect those with poor predicted outcomes to alternative treatments was developed using gene-expression data and validated in two independent datasets. While ...

Lymphoma

Two Cycles of Chemotherapy plus Involved-field Radiation Improves Tumor Control in Early Unfavorable Disease

Charlotte Bath  / May 15, 2012

Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial concluded that intensified chemotherapy with two cycles of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine [Matulane], and prednisone) followed by two cycles of ABVD (doxorubicin, ble...

Breast Cancer

Concepts about Effects of Menopausal Hormone Therapy on Breast Cancer Continue to Change

Charlotte Bath  / May 15, 2012

In 2002, it was thought that menopausal hormone therapy using estrogen alone increases breast cancer risk, although not as quickly as combined estrogen plus progestin. Current thinking about estrogen alone is that it reduces breast cancer risk. This is just one example of changing concepts about men...

Breast Cancer

Women Treated with Breast-conserving Surgery More Likely to Have Diagnostic and Invasive Procedures over Time

Charlotte Bath  / May 15, 2012

Women with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery “continue to have diagnostic and invasive breast procedures in the conserved breast over an extended period,” according to a study reported in the Journal of the National Cancer Institute. “The estimated 10-year cumula...

Head and Neck Cancer

Younger Patients Treated with Systemic Carboplatin at Higher Risk of Ototoxicity

Charlotte Bath  / May 15, 2012

Patients younger than 6 months at the start of systemic carboplatin treatment for retinoblastoma have a significant risk of developing hearing loss, according to a study in the Journal of Clinical Oncology. A review of audiologic test results of 60 patients with retinoblastoma who received front-lin...

Leukemia

Integrated Genetic Profiling Can Identify Predictors of Outcome and Improve Risk Stratification in AML Patients

Charlotte Bath  / May 15, 2012

A mutational analysis of 18 genes in 398 patients with acute myeloid leukemia (AML) found at least one somatic alteration in 97.3% of the patients and identified genetic predictors of outcome that improved risk stratification among patients with AML, independent of age, white-cell count, induction d...

Kidney Cancer

Partial Nephrectomy Can Optimize Survival in Patients with Early-stage Disease

Charlotte Bath  / May 15, 2012

Following recent clinical trial data from the European Organisation for Research and Treatment (EORTC) showing a survival benefit for patients with small kidney cancers treated with radical vs partial nephrectomy, an analysis using linked Surveillance, Epidemiology and End Results (SEER) and Medicar...

Colorectal Cancer

Adding Cetuximab to Adjuvant Therapy with Modified FOLFOX6 Does Not Improve Survival

The ASCO Post  / May 1, 2012

Adding cetuximab (Erbitux) to adjuvant treatment with mFOLFOX6, the modified sixth version of FOLFOX (leucovorin, fluorouracil, oxaliplatin) did not improve disease-free survival among patients with resected stage III colon cancer, even those with wild-type KRAS, according to a phase III study in th...

Breast Cancer

Sorafenib plus Capecitabine for HER2-negative Advanced Breast Cancer

The ASCO Post  / April 15, 2012

The addition of sorafenib (Nexavar) to capecitabine (Xeloda) improved progression-free survival among women with locally advanced or metastatic HER2-negative breast cancer in a randomized, double-blind, placebo-controlled phase IIB trial. “There was no significant improvement for overall survival,” ...

Breast Cancer

Benefit of Adjuvant Tamoxifen in ER-positive DCIS

The ASCO Post  / April 15, 2012

Retrospective analyses of hormone receptors among patients enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 study showed that women with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who received tamoxifen after standard therapy had significant reduc...

Prostate Cancer

PSA Screening Reduced Prostate Cancer–Specific but Not Overall Mortality

The ASCO Post  / April 15, 2012

“Analyses after 2 additional years of follow-up consolidated our previous finding that [prostate-specific antigen (PSA)]-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality,” investigators from the European Randomized Study of Screening for Pro...

Gastrointestinal Cancer

Salvage Chemotherapy plus Best Supportive Care in Advanced Gastric Cancer

The ASCO Post  / April 15, 2012

Adding salvage chemotherapy to best supportive care was tolerated and improved overall survival among patients with advanced gastric cancer previously treated with both fluoropyrimidines and platinum, administered simultaneously or concurrently. The authors of the study report, published in the Jour...

Issues in Oncology

Higher Intake of Red Meat Associated with Increased Risk of Mortality

The ASCO Post  / April 15, 2012

Eating more red meat appears to be associated with an increased risk of all-cause mortality and death from cancer and cardiovascular disease, but substituting fish, poultry, nuts, legumes, low-fat dairy products, and whole grains for red meat is associated with a lower mortality risk, according to a...

Colorectal Cancer

Survival Advantage of Oxaliplatin Extends to Diverse Group of Patients

The ASCO Post  / March 15, 2012

The survival advantage conferred by adding oxaliplatin to adjuvant chemotherapy with fluorouracil (5-FU), as previously shown in randomized controlled trials, extends to patients in the general population, including older and minority group patients and those with higher comorbidity. These results, ...

VEGFR Tyrosine Kinase Inhibitors Linked to Increased Risk of Fatal Adverse Events

The ASCO Post  / March 15, 2012

A meta-analysis of 10 randomized controlled trials involving 4,679 patients showed that the use of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors was associated with an increased risk of fatal adverse events. “The crude incidence of [fatal adverse events] in patients ...

Breast Cancer

Addition of Bevacizumab to Neoadjuvant Chemotherapy Increases Pathologic Complete Response Rate in HER2-negative Disease

The ASCO Post  / March 1, 2012

Two studies reported in The New England Journal of Medicine showed that the addition of bevacizumab (Avastin) to neoadjuvant chemotherapy significantly increased the pathologic complete response rate in women with HER2-negative breast cancer. In one study, from the German Breast Group, the benefit w...

Gynecologic Cancers

Nearly Identical Survival for Laparoscopy vs Laparatomy in Patients with Stage I/IIA Disease

The ASCO Post  / March 1, 2012

Building on previously reported results that laparoscopic surgical management of uterine cancer is superior for short-term safety and length-of-stay endpoints, the Gynecologic Oncology Group reported small and lower than anticipated potential for increase risk of cancer recurrence with laparoscopy v...

Prostate Cancer

Risk of Sexual and Continence Problems No Lower with Robotic than with Open Surgery

Charlotte Bath  / February 15, 2012

Although robotic-assisted laparoscopic radical prostatectomy “is eclipsing open radical prostatectomy among men with clinically localized prostate cancer,” the risks of problems with sexual functioning and continence are no lower with robotic than open surgery, according to a study in the Journal of...

Lung Cancer

High EGFR Expression Can Predict Survival Benefit from Cetuximab plus First-line Chemotherapy in NSCLC

Charlotte Bath  / February 15, 2012

High expression of epidermal growth factor receptor (EGFR) can predict survival benefit from cetuximab (Erbitux) added to first-line chemotherapy in patients with advanced non–small cell lung cancer (NSCLC). The identification of high EGFR expression as a tumor biomarker follows findings from the ph...

Leukemia

Adding Alemtuzumab to Fludarabine in CLL

The ASCO Post  / January 15, 2012

In a randomized phase III trial among previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), the combination of alemtuzumab (Campath) plus fludarabine resulted in significant improvements in progression-free survival, complete response rate, and overall survival ...

CNS Cancers

Everolimus for Tumors Associated with Carcinoid Syndrome

The ASCO Post  / January 15, 2012

The combination of everolimus (Afinitor) plus octreotide (Sandostatin) long-acting repeatable (LAR) formulation improved progression-free survival by 23% over placebo plus octreotide LAR in a randomized phase III study of patients with advanced neuroendocrine tumors associated with carcinoid syndrom...

Head and Neck Cancer

Chemoradiotherapy for Early-stage Nasopharyngeal Disease

The ASCO Post  / January 15, 2012

Adding chemotherapy to radiotherapy resulted in statistically significantly higher 5‑year overall, progression-free, and distant metastasis-free survival among patients with stage II nasopharyngeal carcinoma in a phase III randomized trial. Adding cisplatin-based chemotherapy to radiotherapy resulte...

Kidney Cancer

Significantly Longer Survival with Axitinib Compared to Sorafenib in Patients with Renal Cell Carcinoma

The ASCO Post  / December 15, 2011

A phase III study comparing the vascular endothelial growth factor receptor (VEGFR) inhibitors axitinib and sorafenib (Nexavar) as second-line therapy in patients with metastatic renal cell carcinoma found that axitinib produced significantly longer progression-free survival. Published in The Lancet...

Breast Cancer
Survivorship

Significant Neurologic and Executive Function Impairment among Breast Cancer Survivors

The ASCO Post  / December 15, 2011

Women who survive breast cancer show significant neurologic impairment, with outcomes appearing to be significantly poorer for those treated with chemotherapy, according to a report in the Archives of Neurology. Investigators at Stanford University School of Medicine in California conducted an obse...

Lung Cancer

Evidence of Improved Survival for Lobectomy vs Limited Resection in Early-stage Lung Cancer

The ASCO Post  / December 15, 2011

“Evidence is statistically inconclusive but suggestive that lobectomy, compared with limited resection, is associated with increased long-term survival for early-stage lung cancer,” according to a study reported in the Journal of the National Cancer Institute. The study analyzed data from 679 pati...

Lymphoma

Intensified Chemotherapy with R-ACVBP Improves Survival in Younger Patients with Diffuse B-cell Lymphoma

The ASCO Post  / January 1, 2012

Compared with standard R-CHOP (rituximab [Rituxan], doxorubicin, cyclophosphamide, vincristine, and prednisone), intensified immunochemotherapy with R-ACVBP (dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine [not available in U.S.], bleomycin, and prednisone) significantly improves ...

Gastrointestinal Cancer

Adjuvant Chemotherapy with S-1 Improves Survival in Stage II/III Gastric Cancer

The ASCO Post  / January 1, 2012

Postoperative adjuvant therapy with the oral fluoropyrimidine derivative S-1 improved overall survival and relapse-free survival in patients with stage II or III gastric cancer who had D2 gastrectomy. Five-year survival rates in the phase III study were 71.7% for patients in the S-1 group vs 61.1% i...

Skin Cancer

Physician-based Screening Leads to the Detection of Thinner Melanomas with More Favorable Prognosis

The ASCO Post  / January 1, 2012

Physician-based screening leads to detection of thinner melanomas that were less likely to have negative prognostic attributes such as ulceration and dermal mitosis, according to a retrospective review of patient records and biopsy logs from 394 patients diagnosed with cutaneous melanoma. The result...

Colorectal Cancer

MRI Helps Predict Survival Outcomes in Patients with Rectal Cancer

The ASCO Post  / November 15, 2011

Magnetic resonance imaging (MRI) can be used after neoadjuvant therapy for rectal cancer to predict survival outcomes for good and poor responders and offer patients additional treatment options before definitive surgery, according to a study conducted at 11 specialist colorectal cancer units in fiv...

Colorectal Cancer

Should Age at Initial Screening Colonoscopy Be Younger for Men?

The ASCO Post  / November 15, 2011

A study to investigate the most appropriate age for initial screening colonoscopy to improve detection of adenomas, advanced adenomas, and colorectal cancer, and lower colorectal cancer mortality found that the most appropriate age might be different for men and women. “In our study, analysis of ag...

Colorectal Cancer

Oxaliplatin Improved Overall Survival in Patients under 70

The ASCO Post  / November 15, 2011

The addition of oxaliplatin to fluorouracil (5-FU) plus leucovorin improved overall survival in patients younger than 70 years old participating in the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial. Patients eligible for the trial had either stage II or III colon cancer and ...

Breast Cancer

Low-level Expression of ESR1 Tied to Tamoxifen Resistance

The ASCO Post  / November 15, 2011

Data from a retrospective analysis of two pivotal breast cancer studies suggest that the low-level expression of the estrogen receptor (ER) gene ESR1 “is a determinant of tamoxifen resistance in ER-positive breast cancer,” reported researchers in the Journal of Clinical Oncology. “We performed gen...

Breast Cancer

Fewer False-positives, Small Increased Risk of Late Diagnosis with Biennial Mammography

The ASCO Post  / November 15, 2011

Screening mammography every other year reduced false-positive recalls by about one-third compared to annual screening, but was associated with a small increase in the probability of late-stage cancer diagnosis, according to a study funded by the NCI and published in Annals of Internal Medicine. To c...

Gynecologic Cancers

Alternative Treatment for Advanced Ovarian Cancer Reduces Neurotoxicity and Alopecia

The ASCO Post  / November 15, 2011

A randomized phase III clinical trial found that carboplatin/pegylated liposomal doxorubicin (Doxil) was not superior in prolonging progression compared to the standard carboplatin/paclitaxel as first-line therapy of patients with advanced ovarian cancer. The carboplatin/liposomal doxorubicin regime...

Head and Neck Cancer

Rates of Surgery and Survival Increasing for Early-stage Cancers

The ASCO Post  / November 15, 2011

Surgery is increasingly being used to treat patients with early-stage laryngeal cancer in the United States, and chemotherapy in combination with radiation therapy is being used increasingly to treat patients in an advanced stage of the disease, according to a report in the October issue of Archives...

Gynecologic Cancers
Geriatric Oncology

Elderly Patients with Ovarian Cancer Least Likely to Receive Chemotherapy

The ASCO Post  / October 15, 2011

An analysis of data for 4,617 women aged 65 years or older diagnosed with epithelial ovarian cancer found that those in the oldest age group, 80 and up, were least likely to receive any chemotherapy. While 53% of patients 80 and older received no chemotherapy, the rate was less than half (22%) for t...

Breast Cancer

Doxorubicin/Cyclophosphamide with Docetaxel Equally Effective in Combination or Sequentially

The ASCO Post  / October 15, 2011

Five-year disease-free survival and overall survival rates were “indistinguishable” in patients with operable, node-positive, HER2-nonamplified breast cancer treated with the sequential or combination regimens of doxorubicin/cyclophosphamide (AC) and docetaxel (T). The Breast Cancer International Re...

Breast Cancer

Comparing Therapies for Managing Hot Flashes in Women with Breast Cancer

The ASCO Post  / October 15, 2011

In a double-blind, placebo-controlled trial, two often-prescribed treatments recommended in clinical guidelines for the management of hot flashes were found to be effective in managing hot flashes in patients with breast cancer. Patient-reported hot flash scores showed that venlafaxine, a selective ...

Breast Cancer

Replacing Epirubicin with Docetaxel for Three Cycles Improved Outcomes for Node-positive Breast Cancer

The ASCO Post  / October 15, 2011

Substituting docetaxel for epirubicin in the final three cycles of chemotherapy resulted in improvement in disease-free and overall survival in a trial among postmenopausal women with node-positive early breast cancer. Following complete excision, women enrolled in the Docetaxel Epirubicin Adjuvant ...

Colorectal Cancer

Hepatic Resection Remains Preferred Strategy for Colorectal Liver Metastases

The ASCO Post  / October 15, 2011

Hepatic resection was shown to be superior to radiofrequency ablation (RFA) for the treatment of colorectal liver metastases, according to a model used to stimulate a randomized controlled trial. Researchers from the Hepatobiliary and Pancreatic Surgery Program at the Providence Portland Medical Cen...

Issues in Oncology

Cancer Information on Wikipedia as Accurate as on PDQ but Harder to Understand

The ASCO Post  / October 15, 2011

A comparison of cancer information on Wikipedia and the patient version of information on the NCI’s Physician Data Query (PDQ) “found that although Wikipedia had similar accuracy and depth to the PDQ, the written style was more complex and thus might be less understandable to patients.” According to...

Thyroid Cancer

Wide Variation in Use of Radioactive Iodine for Thyroid Cancer

The ASCO Post  / September 15, 2011

The proportion of patients with well-differentiated thyroid cancer who received radioactive iodine following total thyroidectomy increased significantly since 1990, and there is wide variation in the use of adjuvant radioactive iodine, according to a study in the Journal of the American Medical Asso...

Prostate Cancer

Androgen Deprivation plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

The ASCO Post  / September 15, 2011

Adding short-term androgen-deprivation therapy to radiotherapy “conferred a modest but significant increase in the 10-year rate of overall survival, from 57% to 62%,” in men with localized prostate cancer enrolled in Radiation Therapy Oncology Group (RTOG) trial 94-08. “This increase was accompanied...

Breast Cancer

Comorbidities Can Be as Important as Stage in Predicting Breast Cancer Survival in Older Patients

The ASCO Post  / September 15, 2011

Comorbidities can be as important as stage in predicting survival among older women with breast cancer, according to a study in the Journal of the National Cancer Institute. While previous studies have combined comorbidities into a summary measure or comorbidity index, the current study assessed the...

Breast Cancer

Patients with HER2-positive Breast Cancer Benefit from Trastuzumab plus Chemotherapy

The ASCO Post  / September 15, 2011

Adding trastuzumab (Herceptin) to standard anthracycline/taxane–based chemotherapy continued to produce disease-free and overall survival benefits in patients with HER2-positive breast cancer enrolled in the North Central Cancer Treatment Group (NCCTG) N9831 and the National Surgical Adjuvant Breast...

Breast Cancer

Unexpected Results May Push Breast Cancer Research toward More Productive Approaches

The ASCO Post  / September 15, 2011

Two recent articles on breast cancer prognostic factors in the Journal of Clinical Oncology “do not jibe with accepted—and profoundly influential—notions of malignant progression,” according to an editorial accompanying the articles in the Journal of Clinical Oncology. One of the articles found that...

Lung Cancer

Identifying Genetic Factors That Predict Response to Chemotherapy in NSCLC

The ASCO Post  / September 1, 2011

A genetic variation in the chemokine-like receptor 1 (CMKLR1) gene was statistically significantly associated with poor overall survival in patients with non–small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy with or without radiation. The variation was identified by a ...

Prostate Cancer

Androgen Deprivation Therapy plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

The ASCO Post  / September 1, 2011

The addition of short-term androgen deprivation therapy to radiotherapy for men with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen (PSA) level of 20 ng/mL or less “conferred a modest but significant increase in the 10-year rate of overall survival, from 57 to 62...

Bladder Cancer

Neoadjuvant Chemotherapy with CMV Improves Outcome for Invasive Bladder Cancer

The ASCO Post  / September 1, 2011

Long-term results from a phase III trial show that neoadjuvant chemotherapy with CMV (cisplatin, methotrexate, and vinblastine) improves the outcome for patients with muscle-invasive urothelial cancer of the bladder treated by cystectomy and/or radiotherapy. “Three cycles of CMV before cystectomy o...

Colorectal Cancer

Surgical Site Infections after Colectomy More Likely in Obese Patients

The ASCO Post  / September 1, 2011

Obese patients appear to have a significantly increased risk of developing a surgical site infection after segmental or total colectomy for colon cancer, diverticulitis, or inflammatory bowel disease, and the presence of infection increases the cost associated with the procedure, according to a repo...

Colorectal Cancer

Venous Thromboembolism More Frequent after Open Colorectal Surgery than Post-laparoscopy

The ASCO Post  / August 15, 2011

The risk of developing venous thromboembolism (VTE) may be nearly twice as high for patients undergoing open colorectal procedures as for those undergoing laparoscopic colorectal resections, according to a report in the Archives of Surgery. The authors also “identified malignancy, obesity, and conge...

Colorectal Cancer

Endoscopic Excision May Be Viable Alternative to Surgical Resection of Large Colorectal Polyps

The ASCO Post  / August 15, 2011

A retrospective review of 104 consecutive patients with large colorectal lesions, including 39 with carcinoma, found that “endoscopic excision of large colorectal polyps is a viable alternative to surgical resection in a select group of patients and can be performed safely with a good success rate.”...

Breast Cancer

Higher Risk of Recurrence for Triple-negative Breast Cancer after Modified Radical Mastectomy without Radiation

The ASCO Post  / August 15, 2011

“The paucity of therapeutic options” for women with triple-negative breast cancer “emphasizes the urgent need to optimize the current locoregional management of patients with [triple-negative breast cancer] and reduce their risk of locoregional recurrence,” noted the authors of a Canadian study repo...

Multiple Myeloma

Subcutaneous Bortezomib Offers Improved Safety Profile for Treating Patients with Relapsed Multiple Myeloma

The ASCO Post  / June 15, 2011

Subcutaneous administration of bortezomib (Velcade) was comparably efficacious to intravenous administration in a phase III trial in patients with relapsed multiple myeloma, but the SC route “seemed to have an improved systemic safety profile compared with intravenous delivery,’’ investigators repor...

Prostate Cancer

Death Rates Significantly Reduced for Men Having Radical Prostatectomy vs Watchful Waiting

The ASCO Post  / June 15, 2011

Estimated 15-year results from the Scandinavian Prostate Cancer Group Study (SPCG-4) show that men diagnosed with early prostate cancer and randomly assigned to radical prostatectomy continued to have significantly reduced rates of death from prostate cancer, death from any cause, and risk of metast...

Gynecologic Cancers

Adding Gemcitabine to Chemoradiation Improves Survival Outcomes for Locally Advanced Cervical Cancer

The ASCO Post  / June 15, 2011

A phase III, open-label, randomized trial found that adding gemcitabine to concurrent cisplatin chemoradiotherapy and using gemcitabine as adjuvant chemotherapy with cisplatin improved survival outcomes in women with locally advanced cervical cancer. Toxicity was increased compared to standard treat...

Lung Cancer

Statistically Significant Decline in Lung Cancer Incidence and Death Rates among Women

The ASCO Post  / June 15, 2011

More than a decade after lung cancer incidence and death rates began to decline in men, a statistically significant decrease in the rates are occurring among women. The Annual Report to the Nation on the Status of Cancer, 1975 to 2007, is the first to document these decreases, the report’s authors n...

Kidney Cancer

Sunitinib-induced Hypertension May Be Efficacy Biomarker in Patients with Metastatic Renal Cell Carcinoma

The ASCO Post  / June 15, 2011

A retrospective exploratory analysis of pooled efficacy data from more than 500 patients with metastatic renal cell carcinoma treated with sunitinib (Sutent) “support the hypothesis that hypertension may be a viable biomarker of antitumor efficacy in this patient population,” according to a report i...

Advertisement

Advertisement



Advertisement